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There is a high comorbidity of type-2 diabetes and neuropsychiatric disorders. However, there is 
paucity of preclinical research to study this phenomenon. The validity of the db/db mouse as an 
animal model to study type-2 diabetes and related macrovascular and microvascular 
complications is well established. The first part of this dissertation was designed to investigate 
comprehensively the db/db mouse behavior as preclinical evidence of type-2 diabetes related 
major neurobehavioral complications. Juvenile (5–6 weeks) and adult (10–11 weeks) db/db mice 
were screened for behavioral depression in forced swim test (FST), psychosis-like symptoms 
using pre-pulse inhibition (PPI) test, anxiety behavior employing elevated plus maze (EPM) test, 
locomotor behavior and thigmotaxis using open field test, emotional learning using fear 
potentiation of startle (FPS) test and working memory deficits in Y-maze test. Both juvenile and 
adult group db/db mice displayed behavioral despair with increased immobility time in FST. 
There was an age-dependent progression of psychosis-like symptoms with disrupted PPI in adult 
db/db mice. In the EPM test, db/db mice were less anxious as observed by increased percent 
open arms time and entries. They were also hypolocomotive as evident by a decrease in their 
basic and fine movements. There was no impairment of working memory in the Y-maze test in 
db/db mice. In the FPS test, db/db mice showed impaired learning response indicative of 
abnormalities in DA neuronal activity in the amygdala. 
The second specific aim of this dissertation was to examine possible neurochemical basis 




norepinephrine (NE) and serotonin (5-HT) are elemental to normal functioning of the brain. 
Current theories of the basis for major neurobehavioral disorders involve abnormalities in use of 
NE, 5-HT and DA in specific brain regions. Recent studies report that the DA agonist reverses 
diabetes-related metabolic abnormalities, thus suggesting that DA abnormalities may provide a 
link to underlying the psychiatric and endocrine disorders in type-2 diabetics. To evaluate type-2 
diabetes related neurochemical alterations, concentrations of NE, 5-HT, DA and its catabolites 
homovanilic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) were measured in the 
frontal cortex, amygdala, hippocampus, hypothalamus and brainstem of db/db mice by reverse-
phase high performance liquid chromatography (HPLC). There was abnormal DA metabolism 
pattern in the frontal cortex and amygdala of db/db mice that correlated with their psychosis-like 
behavior and impaired FPS response. Moreover, type-2 diabetes related changes in the 
expression of DA biosynthesis rate determining step (RDS) enzyme tyrosine hydroxylase (TH) 
were studied using western blot technique. No changes in TH expression pattern were seen in the 
frontal cortex and amygdala of db/db mice compared to age-matched lean controls. Thus, 
abnormal DA metabolism pattern in these brain regions of db/db mice may be related to changes 
in the enzymatic activity of DA metabolizing enzymes and/or firing pattern of DAergic neurons. 
The third specific aim of this research project was to examine the effect of long-term 
management of insulin resistance and hyperglycemia on neurobehavioral deficits in db/db mice. 
Rosiglitazone mixed in chow was administered to 5 week old db/db and lean control mice (20 
mg/kg/day) for duration of 5 weeks. Separate groups of age-matched db/db and lean control mice 
were fed with standard chow. Mice were weekly monitored for blood glucose concentration. 
Five weeks after treatment onset, the mice were subjected to the forced swim test (FST), pre-




behavioral depression, psychosis-like behavior, locomotor activity and emotional learning, 
respectively. Rosiglitazone-induced reversal of depression- but not psychosis-like behavior and 
impaired emotional learning in db/db mice. 
The final specific aim of this project was to evaluate the effect of controlling insulin 
resistance and hyperglycemia on DA biosynthesis RDS enzyme TH, DA metabolism pattern and 
5-HT and NE concentrations in selective brain regions of db/db diabetic mice. Rosiglitazone 
treatment resulted into restoration of the abnormal DA metabolism in the frontal cortex and 
amygdala of db/db mice to normal. 
 The principal findings of this dissertation report are: (1) db/db mice exhibit behavioral 
depression, age-dependent advancement of psychosis-like symptoms, impaired emotional 
learning and anxiolytic behavior; (2) abnormal DA metabolism pattern in the frontal cortex and 
amygdala of db/db mice that correlated with behavioral deficits; (3) rosiglitazone-induced 
reversal of depression- but not psychosis-like behavior and impaired emotional learning in db/db 
mice; and (4) restoration of the majority of changes observed in DA metabolism in the brains of 
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Diabetes mellitus is an endocrine metabolic disorder characterized by persistent hyperglycemia 
due to abnormalities in insulin secretion, insulin action or both. The occurrence of diabetes 
across the globe has grown at an alarming pace in the last decade. The World Health 
Organization (WHO) estimates that by the year 2030 around 370 million people worldwide will 
suffer with diabetes (Wild et al., 2004). Diabetes alone represents 11% of the total US healthcare 
expenditures (Hogan et al., 2003). During the last decade diabetes was sixth among fifteen of the 
most expensive health conditions in Unites States and second in terms of direct cost for 
individuals on medical treatment (Cohen and Krauss, 2003). Moreover, diabetes ranks sixth 
among major leading causes of death in the Unites States (Centers for Disease Control and 
Prevention).  
 
1.1. Classification of diabetes 
Diabetes can be divided into two main subtypes: (a) Type-1 diabetes was previously known as 
juvenile onset diabetes. It is an autoimmune disorder characterized by antibodies against insulin 
producing pancreatic -cells resulting in insulin deficiency. -cell specific antibodies appear 
long before the onset of type-1 diabetes. Approximately 10 percent of the diabetic population 
suffers from type-1 diabetes. (b) Type-2 diabetes was in the past referred to as mature onset 
diabetes. Type-2 diabetes accounts for around 90% of the diabetic population. It is a 
heterogeneous disorder which is generally the by-product of an interaction between 
environmental factors and genetic predisposition. There is reduced response to insulin by target 
tissues. Although blood insulin levels in type-2 diabetes patients are higher than type-1 diabetic 




target organs to insulin. Though insulin levels are higher, they are not sufficiently high enough to 
overcome the insulin resistance observed in target organs like liver, muscle and adipose tissue. 
Thus, there is absolute insulin deficiency in type-1 diabetes while there is relative insulin 
deficiency in type-2 diabetes. Therefore, type-2 diabetes is currently considered to be a result of 
reduced insulin secretion plus target organ insensitivity to insulin.  
1.2. Diabetes and co-morbid complications 
Diabetes associated co-morbid complications can prove expensive as well as life threatening to 
diabetic patients. Individuals with co-morbid conditions account for 95% of inpatient 
hospitalizations for diabetes than diabetes alone. Diabetic patients are highly susceptible to 
cardiovascular system (CVS) disease, renal disease, neurological disorders, peripheral vascular 
disease, endocrine complications and retinopathies.  
Diabetes related co-morbid central nervous system (CNS) complications 
In addition to cardiovascular complications of diabetes, co-morbid neurobehavioral deficits 
create additional challenges to patients and healthcare practitioners. Many clinical reports have 
shown co-morbidity of type-2 diabetes with major neuropsychiatric disorders. Depression (Eaton 
et al., 1996; Kawakami et al., 1999; Musselman et al., 2003), schizophrenia (Cohen et al., 2006; 
Dickerson et al., 2008; Levitt Katz et al., 2005; Lin and Shuldiner, 2010), anxiety (Collins et al., 
2009) and cognitive impairment (Gispen and Biessels, 2000) are some of the major 
complications associated with  diabetes.  
 
1.3. Diabetes and depression 
Behavioral depression is the most common co-morbid disorder in the diabetic population (Katon, 




compared to the non-diabetic population (Anderson et al., 2001). Additionally, depressed 
patients are 37% more vulnerable to the onset of type-2 diabetes compared to non-depressed 
subjects (Knol et al., 2006). Further, among diabetic patients, individuals with co-morbid minor 
or major depression are at greater risk of mortality. Minor depression plus diabetes increases 
mortality 1.67 fold while major depression plus diabetes increases mortality 2.3 fold. Such 
depression associated increased mortality in diabetic patients may be linked to biological, 
neurochemical and behavioral factors. Behavioral despair in diabetic patients can lead to apathy 
towards self-care regimens such as regular exercise, dietary habits, cessation of smoking and 
towards medication for diabetes as well (Lin et al., 2004). Moreover, diabetic patients with co-
morbid depression are reported to have doubled probability of cardiac risk factors like smoking, 
obesity, sedentary lifestyle etc (Katon et al., 2004). Interestingly, one meta-analysis study linked 
depressive symptoms in diabetic subjects to poor glucose regulation (Lustman et al., 2000).  
 
1.4. Diabetes and schizophrenia 
The co-morbidity of diabetes and schizophrenia has been acknowledged for more than 130 years. 
Sir Henry Maudsley famously quoted in his book ‘The pathology of mind’ that ‘Diabetes is a 
disease which often shows itself in families in which insanity prevails’ (Maudsley H, 1879). 
Peveler and Fairburn suggested that for the effective management of diabetes, treatment of co-
morbid mental illness is necessary (Peveler and Fairburn, 1989). There is a 17-50% probability 
of developing schizophrenia in the  type-2 diabetic population or in people with a family history 
of type-2 diabetes (Mukherjee et al., 1989). Moreover, a higher incidence (~20 percent) of 
schizophrenia, attention deficit hyperactivity disorder (ADHD), bipolar disorder, depression and 




et al., 2005). In the year 2003, a group of diabetologists and psychiatrists discussed the co-
morbidity of diabetes and schizophrenia and developed guidelines to deal with their association 
(Holt, 2004). Co-morbid type-2 diabetes is reported to impair physical as well as mental health 
status in adult schizophrenic patients compared to non-diabetic schizophrenics (Dickerson et al., 
2008; Dickinson et al., 2008). The pioneer work showing an association between the use of 
typical antipsychotic medications and the development of type-2 diabetes was made in 1956 
(Hiles, 1956). This led to the introduction of the term ‘phenothiazine diabetes’. The emergence 
of new-onset diabetes was also reported in schizophrenic patients after initiation of atypical 
antipsychotic medications (Lambert et al., 2006; Ramaswamy et al., 2006; van Winkel et al., 
2008). Hyperglycemia and insulin resistance was also reported in mice that received chronic 
antipsychotic treatment (Dwyer and Donohoe, 2003). Recently van Nimwegen and co-workers 
showed that antipsychotic-naive schizophrenics also experience insulin resistance compared to 
non-schizophrenic controls. Such increased propensity towards insulin resistance in 
schizophrenics even when not medicated may be the outcome of metabolic abnormalities (van 
Nimwegen et al., 2008). These findings hint toward a bidirectional link between diabetes and 
schizophrenia. Surprisingly, there are no preclinical attempts to examine the development of 
psychosis-like behavior in animal models for type-2 diabetes. Despite all the recent interest in 
the potential link between diabetes and schizophrenia, the underlying mechanisms for their co-
morbidity remains poorly understood.  
 
1.5. Diabetes and anxiety 
A comprehensive meta-analysis of scientific literature suggest that anxiety disorders are directly 
linked with diabetes related hyperglycemia (Anderson et al., 2001). A recent large-scale 




development of type-2 diabetes (Engum, 2007). Further, high anxiety scores (Collins et al., 
2009) and an increased prevalence of generalized anxiety disorder were reported in type-2 
diabetic patients relative to non-diabetic adults (Fisher et al., 2008). For most of type-2 diabetic 
patients, emotional problems such as anxiety remain largely undetected (Pouwer, 2009). Because 
of the lack of awareness of this co-morbidity there is a dearth of intervention studies to treat such 
co-morbid symptoms (Pouwer, 2009). Alternatively, Labad and colleagues recently have shown 
that depression but not anxiety is associated with type-2 diabetes (Labad et al., 2010). Thus, 
clinical studies evaluating anxiety levels in type-2 diabetic patients led to conflicting outcomes. 
There are few preclinical reports that attempted to study anxiety behavior in animal models of 
diabetes. In spontaneously diabetic INS2
Akita
 mouse, Asakawa and colleagues reported anxiety-
like behavior using the elevated plus maze test (Asakawa et al., 2007). Further, type-2 diabetic 
ob/ob mice were reported to exhibit anxiety behavior (Asakawa et al., 2007; Finger et al., 2010). 
Exploring the biological mechanisms that govern anxiety-like behavior using mouse model for 
type-2 diabetes may help to improve our understanding about their co-morbidity.  
 
1.6. Diabetes and cognition 
Cognitive deficits are found in type-2 diabetic mice (Li et al., 2002) and are also prevalent in 
type-2 diabetic patients (Gispen and Biessels, 2000). db/db mice have impaired spatial memory 
task performance in the Morris water maze test (Li et al., 2002). While the frontal cortex is the 
anatomical site for working memory, the hippocampus's role as the substrate for spatial memory 
functions is well documented (Bohlen und et al., 2006; Courtney et al., 1998). Recently, 
Stranahan and colleagues reported diabetes-induced detrimental effects on hippocampal neurons, 




energy expenditure in insulin-resistant db/db mice (Stranahan et al., 2009). Elevations in 
corticosterone levels (Stranahan et al., 2008) as well as reduced hippocampal brain-derived 
neurotrophic factor (BDNF) levels (Stranahan et al., 2009) are suggested as crucial mechanisms 
for diabetes-related cognitive deficits. Ohta and colleagues using a conditioned taste aversion 
(CTA) learning test found that impaired downstream signaling due to the mutation in leptin 
receptors in db/db mice had no effect on acquisition of CTA learning but promoted faster 
extinction (Ohta et al., 2003). Yamamoto suggested that the parabrachial nucleus, amygdala, 
insular cortex, supramammillary nucleus, nucleus accumbens, and ventral pallidum as possible 
anatomical sites for CTA learning in rats (Yamamoto, 2007). 
 
1.7. Diabetes and stress 
Emotional stress has long been considered as a risk factor for the development of diabetes. The 
English physician Thomas Willis commented that diabetes is more common in people that had 
experienced emotional stress (Willis, 1675). Stress may be an important contributing factor to 
the development of diabetes and co-morbid disorders (Castaneda et al., 2011; Trento et al., 
2010). Recently in a mouse model of post-traumatic stress disorder (PTSD), Castaneda and co-
workers reported impaired glucose tolerance (Castaneda et al., 2011). Measurement of glycated 
hemoglobin (HbA1C) is a laboratory test used to determine average blood glucose concentration 
over a prolonged time. According to the American Diabetes Association, HbA1C ≥6.5% is the 
confirmatory test for diagnosis of diabetes. In a cross-sectional study there was a strong 
association between lifetime PTSD symptoms in low-income patients and > 7% HbA1C levels 
(Miller et al., 2011). Alternatively, PTSD is a risk factor for the development of diabetes (Weiss 





1.8. Impact of insulin resistance and hyperglycemia on brain functions 
Multiple clinical studies suggest a close relationship between insulin resistance, hyperglycemia 
and neuropsychiatric disorders (Anderson et al., 2001; Cohen et al., 2006; Collins et al., 2009; de 
la Monte et al., 2009; Gispen and Biessels, 2000; Hall et al., 2009; Koopmans et al., 2009; 
Pouwer, 2009). Peripheral insulin resistance correlates with insulin insensitivity in the brain and 
increases the vulnerability of neurons to degeneration. In streptozotocin-induced diabetic rats, 
insulin treatment normalizes hyperglycemia-induced deficits in nerve conduction velocity 
(Huang et al., 2003). Several studies suggested a regulatory role for insulin in brain glucose 
metabolism, neurobehavioral functions and inflammatory responses in the CNS. Diabetes 
associated insulin resistance and hyperglycemia affects neuronal morphology (Malone et al., 
2008) and severely damages the brain (Jacob et al., 2002). Hyperglycemia amplifies brain levels 
of oxidative stress markers and induces inflammation (Tsuruta et al., 2010). Such close 
integration between insulin resistance and brain functions suggests that improving insulin 
sensitivity and normalization of hyperglycemia may help to overcome some of the damage and 
neurobehavioral outcomes. Rosiglitazone, a selective agonist at peroxisome proliferator activated 
gamma (PPAR receptors improves insulin-sensitivity of target organs. Rosiglitazone also 
lowers the severity of depression in insulin-resistant depressed patients (Rasgon et al., 2010). 
Moreover, rosiglitazone in type-2 diabetics can improve working memory performance (Ryan et 
al., 2006). The PPAR receptor agonist pioglitazone produced antidepressant-like effects in non-
diabetic mice, while administration of a PPAR antagonist prior to pioglitazone attenuated this 
effect (Sadaghiani et al., 2011). These results suggest that PPAR receptor activation in the brain 




effect on blood glucose. Further, a neuron-specific PPAR receptor knockout in high-fat diet 
mice decreased rosiglitazone-induced improvement in glucose metabolism (Lu et al., 2011) 
suggesting a role of central PPAR receptors in hepatic insulin sensitivity.  
1.9. Dopamine as a novel factor in type-2 diabetes complications 
There is a rapidly growing interest in the involvement of DA in the pathophysiology of type-2 
diabetes. Administration of a DA neurotoxin into the brain induces insulin resistance (Luo et al., 
1997; Pijl, 2003). There is decreased DA neurotransmission and DA receptor sensitivity in 
rodent models for diabetes (Cincotta et al., 1997; Rutledge et al., 2002). Type-2 diabetic Zucker 
fa/fa rats have diminished D2R expression in the hypothalamus (Fetissov et al., 2002), decreased 
DA levels, and impaired post-synaptic DA action (Meguid et al., 2000). Type-2 diabetic ob/ob 
mice have   diminished locomotive response to amphetamine (Fulton et al., 2006). Further, D2R 
knockout mice have an impaired insulin response to glucose, high fasting glucose and glucose 
intolerance (Garcia-Tornadu et al., 2010a). Interestingly, 4-week rosiglitazone treatment (10 
mg/kg) to Zucker fa/fa rats has been shown to restore renal D1R number and dopamine mediated 
urinary sodium excretion (Umrani et al., 2002). Clinical and preclinical reports suggest region-
specific alterations in DA and its catabolites in the diabetic brain (Lackovic et al., 1990). 
Interestingly, activation of D2Rs in the ob/ob mice helped to lower diabetes-related metabolic 
abnormalities (Cincotta et al., 1997). Recently, the FDA approved the use of the D2R agonist, 
bromocriptine, for the treatment of type-2 diabetes (de Leeuw van Weenen JE et al., 2010; 
Gaziano et al., 2010; Scranton and Cincotta, 2010). D2R agonist can normalize hyperglycemia 
and glucose-stimulated insulin secretion (de Leeuw van Weenen JE et al., 2010; Liang et al., 




serotonin reuptake inhibitors (Renard et al., 2001) and is well known to stimulate motor behavior 
(Bruhwyler et al., 1991).  
Tyrosine Hydroxylase  
 Tyrosine hydroxylase (TH) is the rate-limiting enzyme for the biosynthesis of DA. In addition to 
changes in DA neurotransmission, receptor sensitivity and metabolite concentrations, a fall in 
TH levels was reported in ob/ob diabetic mice brain (Fulton et al., 2006). There are few studies 
that attempted to study diabetes-induced changes in brain TH activity. Type-1 diabetic rats show 
increased TH expression in the cerebral hemispheres, cerebellum, brainstem and olfactory lobes 
(Gupta et al., 1992). Further, TH expression was increased in the locus coeruleus but decreased 
in the ventral tegmental area (VTA) and substantia nigra of type-1 diabetic rats (Figlewicz et al., 
1996). Also, structural deformities in nerve fibers containing TH were reported in type-1 diabetic 
rats (Tsai et al., 2008). Few laboratories have looked for type-2 diabetes related changes in TH in 
only selected brain regions. A fall in TH concentration was reported in the nucleus accumbens 
(NAc) and VTA of leptin-deficient ob/ob mouse brain (Fulton et al., 2006). However, TH 
immunoreactivity in neurons of Zucker fa/fa rats were not different from that of lean control rats 
(Fetissov et al., 1997). Thus, changes in TH expression in type-2 diabetic brain may be region-
specific or model specific. Evaluation of TH concentrations in different brain regions of db/db 
mice could help us to understand role of this enzyme in progression of type-2 diabetes related 




1.10. Dopamine in the brain 
Dopamine biosynthesis and metabolism 
Abbreviations: DOPA – Dihydroxyphenylalanine; DA – Dopamine; MAO – Monoamine 
Oxidase; DOPAC – Dihdroxyphenylacetic Acid; COMT  –  Catechol –O –Methyl Transferase; 
3-MT – 3-Methyltyrosine; HVA – Homovanillic Acid; DAR – Dopamine Receptor; G – G-
Protein.  
 
DA is a key neurobiological substrate involved in schizophrenia (Moncrieff, 2009; Remington, 
2008) and depression (Butler and Meegan, 2008; Guiard et al., 2009). A decline in cerebrospinal 
fluid HVA concentration, a major DA metabolite, was reported in suicide attempters and 
depressed patients relative to controls (Engstrom et al., 1999; Volkow et al., 2000). However, the 
DA concentrations in the brains of suicidal victims remain unaffected suggesting reduced DA 
metabolism (Bowden et al., 1997). Antidepressant treatment increases D2R density in the rat 
brain (Dziedzicka-Wasylewska et al., 1997). Further, schizophrenics have reduced DA 




Weinberger et al., 1988). The brain regions that we planned to study for changes in DA 
metabolism all receive dopaminergic neuronal projections (Bjorklund et al., 1975; Lazar et al., 
2008; Mehler-Wex et al., 2006; Nakasato et al., 2008; Stevenson and Gratton, 2004; Villablanca, 
2010). DA in the frontal cortex (FC) regulates some behaviors such as pre-pulse inhibition of 
startle (PPI) (Lazar et al., 2008; Mehler-Wex et al., 2006; Nakasato et al., 2008). DA 
hypoactivity in the FC induces psychosis-like behavior as well as impairment of pre-pulse 
inhibition of startle (Bacopoulos et al., 1979; Davis et al., 1991). The amygdala, a component of 
the mesolimbic DA system, participates in conditioned fear (Fadok et al., 2009) and  fear 
potentiation of startle (FPS) (Stevenson and Gratton, 2004) behaviors. Caudate DA coordinates 
voluntary movements (Villablanca, 2010) and DA hypoactivity in the caudate can promote hypo 
–locomotion. The hippocampus is a primary component of the mesolimbic dopaminergic system 
involved in cognitive functions and dopaminergic projections to the hypothalamus regulates 
neuroendocrine functions (Bjorklund et al., 1975).  







1.11. Dopamine and glucose metabolism 
Changes in DA neurotransmission have been shown to have a great impact on glucose 
metabolism (Cincotta and Meier, 1996; Cincotta et al., 1997). Insulin resistant animal models 
have reduced DA neurotransmission in the brain (Lemierre et al., 1998; Meguid et al., 2000; 
Orosco et al., 1995) and decreased DA receptor expression in the hypothalamus and striatum 
(Fetissov et al., 2002; Pijl, 2003; Wang et al., 2001). DA neurotoxins induce insulin resistance 
(Luo et al., 1997). Insulin resistant ob/ob mice have reduced DOPAC/DA ratios in the frontal 
cortex and brainstem and increased HVA/DA ratios in the frontal cortex and hypothalamus 
(Harris et al., 1998). A clinical report also suggests region-specific alterations in DA and its 
catabolites in the brains of diabetic patients (Lackovic et al., 1990). Interestingly, activation of 
D2Rs in the insulin resistant ob/ob mice helped to lower diabetes-related metabolic abnormalities 
(Cincotta et al., 1997). Further, the majority of current antipsychotic medications that are D2R 
antagonists promote hyperglycemia, insulin-resistance and weight gain, which worsens pre-
existing diabetes and related complications (De Hert and Cohen, 2009; Dwyer et al., 2001; 
Dwyer and Donohoe, 2003; Lipscombe et al., 2009). Thus, insulin resistance and hyperglycemia 
could impair DA biosynthesis and/or metabolism in the selective brain regions of db/db mice. 
Approaches to improve insulin sensitivity may help to overcome some of these type-2 diabetes 





2. Development of hypothesis 
 
A substantial body of research points to an increased risk of brain disorders such as depression 
and schizophrenia in type-2 diabetic patients. However, the underlying mechanisms for such co-
morbidity remain poorly understood. Insulin resistance is the hallmark feature of type-2 diabetes. 
Insulin sensitizers such as rosiglitazone lower insulin resistance and hyperglycemia in type-2 
diabetic patients. In addition to their antidiabetic effect, insulin sensitizers are shown to reverse 
depression and improve working memory performance. Compelling evidences links type-2 
diabetes to impairments in dopamine (DA) signaling. DA receptor agonists normalize 
hyperglycemia and insulin secretion. Further, DA receptor antagonists augment insulin resistance 
and hyperglycemia. DA also plays a critical role in the pathophysiology of schizophrenia and 
depression. The co-localization of insulin and DA receptors in several brain regions opens the 
possibility of insulin regulation of DA neurotransmission in the diabetic brain. We hypothesize 
that insulin resistance impairs DA biosynthesis and metabolism in selective brain regions and 
this could contribute to type-2 diabetes related neurobehavioral deficits. Improvement of insulin 
sensitivity and control of hyperglycemia may reverse type-2 diabetes related selective behavioral 
and neurochemical deficits. The db/db mouse is an animal model for type-2 diabetes which has 
the characteristic insulin resistance and hyperglycemia.  
The central hypothesis is: Type-2 diabetic db/db mice experience behavioral and 
neurochemical (dopaminergic) deficits. Effective management of insulin resistance and related 





  Hypothesized mechanism 
  
db/db mice 
1. Mutated leptin receptor 
2. Insulin resistance 
3. 3. Hyperglycemia 
Type-2 diabetes phenotypes 
Neurobehavioral complications 







Correction of type-2 diabetes phenotypes 
Reversal of neurobehavioral complications 




3. Specific aims 
Specific aim 1: To test the hypothesis that type-2 diabetic db/db mice have neurobehavioral 
deficits.  
db/db mice were used as a model to evaluate behavioral and diabetic phenotypes. Mice were 
screened for depression, psychosis, anxiety, locomotion, working memory and emotional 
learning. A battery of six behavioral tests was used to meet this objective. 
 
Specific aim 2: To test the hypothesis that db/db mice have altered DA biosynthesis and/or 
metabolism in selective brain regions.  
Brain regions such as the frontal cortex, amygdala, hippocampus, hypothalamus and brainstem 
were evaluated for DA biosynthesis and metabolism patterns. Reverse-phase high performance 
liquid chromatography (RP-HPLC) was used to measure concentrations of DA and its 
metabolites HVA and DOPAC in selected brain regions with DA neuronal projections. Western-
blots were used to examine type-2 diabetes related changes in DA biosynthesis RDS enzyme TH. 
 
Specific aim 3: To test the hypothesis that improving insulin sensitivity and effective 
management of hyperglycemia will reverse some of neurobehavioral deficits in db/db mice. 
 
db/db mice were fed with rosiglitazone to improve insulin sensitivity and blood glucose 
concentrations. Selective behavioral tests were run based on specific aim 1 experimental results 
to study the impact of improving insulin sensitivity and normalization of hyperglycemia on 
neurobehavioral deficits in db/db mice. 
 
 
Specific aim 4: To test the hypothesis that improving insulin sensitivity and effective 




the db/db mouse brain. The effect of improving insulin sensitivity on DA biosynthesis and 
metabolism pattern was studied in selective brain regions with DA neuronal projections. 
 









4. Materials and methods 
 
4.1. Animals 





their age-matched non-diabetic lean control mice were procured from Jackson Laboratories (Bar 
Harbor, ME). All the mice were singly housed in plastic cages with wooden shavings in a 
temperature controlled room (22–23 °C) with 12:12 h light : dark cycle (lights off at1700). 
Principles of laboratory animal care were followed and all experimental protocols were approved 
by the Wright State University Animal Care and Use Committee. 
Metabolic parameters 
To assess the metabolic status as an index of progression of diabetes, body weights, food 
consumption and water intake of db/db and lean control mice was monitored weekly. Blood 
glucose (fed), plasma insulin concentrations and body fat composition were measured to verify 
development of diabetes. 
 
4.2. Whole-body fat and lean mass measurements 
The EchoMRI whole body composition analyzer (Houston, TX, USA) was used to determine fat 
and lean body mass of lean control and db/db mice (Taicher et al., 2003). The EchoMRI is a 
QNMR instrument that offers rapid measurement of whole-body composition parameters like 
total body fat, lean mass, body fluids and total body water in live mice without sedation and 
anesthesia. Briefly, EchoMRI instrument was calibrated followed by live mouse placement into a 
plastic cylinder (inside diameter: 4.7 cm; thickness: 0.15 cm). A plastic plunger was used to 
restrain mouse movements except to turn back and about 4 cm vertical movements. Fat and lean 




4.3. Plasma glucose and insulin measurements 
For blood glucose measurements, blood samples were taken from a cut made on the tip of the tail 
and glucose concentration was determined using an Accu-Check Advantage
®
 (Roche Diagnostic 
Corporation, Indianapolis) or Free Style Lite
® 
(Abott Diabetes Care, CA) Blood Glucose 
Monitor. Plasma glucose as well as insulin concentrations were also measured in 10 week old 
db/db mice and their age-matched lean controls that were not fasted. Mice were decapitated, and 
trunk blood was collected in ice-chilled heparinized tubes. Plasma was immediately separated 
and stored at −80 °C. The plasma samples were analyzed at Mouse Metabolic Phenotyping 
Center (Cincinnati, OH) for insulin and glucose according to the manufacturer’s specifications 
(Millipore, St. Charles, MO). 
 
4.4. Glucose tolerance test (GTT) 
To study glucose handling in mice, intra-peritoneal GTT was performed. Mice were fasted for 16 
hours. Fasting blood glucose was measured after the end of fasting period. Mice were then 
injected with glucose (1.5 mg/kg, ip). Blood samples were taken from mouse tail vein at 15, 30, 
45, 60, 90 and 120 minutes after intraperitoneal glucose injection. These blood samples were 
analyzed for glucose concentration by colorimetric assay using Glucose (GO) Assay Kit 
according to the manufacturer’s specifications (Sigma, Missouri). 
 
4.5. Behavioral studies 
After 1 week acclimatization, mice were subjected to behavioral testing. At two different age 
points (juvenile: 5–6 weeks and adult: 10–11 weeks) separate groups of mice  were subjected to 




fear potentiated startle test and 6) Y-maze test. All the tests were conducted between the hours of 
0900–1400 to minimize circadian influences on mouse behavior. 
 
4.5.a. Forced swim test 
This is a test for evaluating depression-like symptoms. As described previously (Porsolt et al., 
2001) mice were placed in transparent glass cylinders (diameter, 10 cm; height, 25 cm) filled up 
to 10 cm with water (23–25 °C) for 6 min test and scored for duration of immobility. A mouse 
was considered as immobile when floating motionless or making only those movements 
necessary to keep its head above the water. The db/db and lean control mice were tested 
simultaneously in separate cylinders with opaque white plexiglass sheet placed between them so 
that mice could not see each other. During test sessions, mice were video recorded to score 
immobility time. After the swim test, mice were dried with a towel and returned to the home 
cage placed on a thermal blanket heated to 37 °C. 
 
4.5.b. Pre-pulse inhibition (PPI) test 
This is a test for evaluating psychosis-like behavior. As shown in our previous report (Mach et 
al., 2008), mice were tested in automated startle chambers (SM100 Startle Monitor System 
Version 6.12; Hamilton Kinder, Poway, CA) for pre-pulse inhibition (PPI). There were five 
types of white noise burst stimulus trials: prepulse (70 dB), pulse (85 dB and 100 dB) and pre-
pulse prior to pulse (70 dB+85 dB and 70 dB+100 dB) with background noise (60 dB). Each trial 
type was presented 10 times. Stimuli were presented in random order to avoid order effects and 




rearing behavior and placed on pressure-sensor plates transforming movements of the body 
(jerks) into an analog signal through an interface. 
 
4.5.c. Open field test 
An automated open field system with microprocessor and infrared photo-beams (Hamilton 
Kinder, Motor Monitor Version 3.11; Poway, CA) was used to evaluate locomotor and 
thigmotactic behavior of mice [44]. The open field consisted of 16×16 in (40.6×40.6 cm) 
plexiglass square. For analysis, the chamber was divided into central (8×8 in) and peripheral (4 
in wide) zones. Each mouse was placed in the center of the open field arena and allowed to 
explore it for 10 min. During the 10 min test session, the variables of locomotor activity, basic 
movements (quantified by IR beam interruptions due to larger mouse body movements in the 
open field), fine movements (defined by IR beam interruptions due to fine movements such as 
head-twitching, grooming etc) and percent time spent in periphery and central zones were 
recorded using Motor Monitor software. Open field arena was cleaned with 70% ethanol solution 
and let dry after testing each mouse. 
 
 
4.5.d. Elevated plus maze (EPM) test 
This is a behavioral paradigm that takes advantage of the conflict behavior of rodents between 
exploration of a novel area and aversion to open and elevated spaces (Hata et al., 2001; Pellow et 
al., 1985). The maze is made up of opaque black Plexiglas with opposite facing two open (14×2 
inches) and two enclosed arms (14×2×6 inches) connected by a central platform (2×2 inches). 
The whole maze is raised 30 inches above the floor. Mice were tested on the plus maze in a room 




mouse was placed at the center of the maze with head facing an open arm and allowed to explore 
for 5 min. The number of entries, time spent and distance traveled in each arm were recorded 
with the help of an automated elevated plus maze system (EPM) (Hamilton Kinder, Version 
3.11; Poway, CA). The software was configured to register entry when all four paws of the 
animal were placed on the arm. The maze was wiped clean with 70% ethanol solution and dried 
after testing each mouse. Increase in time spent and frequency of open arms entries relative to 
control mice were considered as indicators of anxiolytic behavior. 
 
 
4.5.e. Y-maze test 
The Y-maze measures a mouse’s functional working memory status and exploits the innate 
tendency to explore novel areas (Ma et al., 2007). The apparatus for Y-maze test was made of 3 
acrylic plastic arms (arm dimensions: 3.5 cm×20 cm) at 120 degrees to each other. During test, 
individual mice were placed on the intersection of 3 arms of the maze and were video recorded 
for 8 min to score the number and sequence of arm entries. An arm entry was registered when all 
four paws of mouse were within any of 3 arms. Entries into 3 different arms in succession (e.g. 
ABC or BCA or CBA or CAB etc) were defined as alternations. Percent Y-maze scores were 
calculated using the formula: 
           Total number of alternations                                                                                                          
=  ----------------------------------   X 100   
           (Total number of entries−2)  
 
 
4.5.f. Fear potentiated startle (FPS) test 
Mice were tested in an automated startle chambers (Kinder Scientific, CA) and loosely restrained 




through an interface. Mice were acclimated to the chamber for 5 min prior to testing. During 
testing 60-decibel (dB) noise as background noise was constantly on. The FPS test consisted of 
three phases: (1) pre-test, (2) training and (3) post-test. Pre-test measures the mouse’s initial 
startle response to 2 different trials i.e. (i) startle stimulus (85 dB white noise startle stimulus) 
and (ii) startle stimulus with tone (70dB, 30 s., 12 kHz pure tone plus 85 dB white noise) with an 
inter-trial interval of 1 min. Each trial was repeated 8 times and presented in randomized fashion 
(total = 16 trials). The % FPS responses for pre-test were calculated using formula: 
=     Startle stimulus alone trials – tone plus startle stimulus   X  100 
      Startle stimulus alone 
 
The training phase was consisted of 20 trials of fear conditioning per day for 2 consecutive days 
[70dB, 30 s., 12 kHz (conditioned stimulus, CS) tone] that overlaps and terminates with a 500 ms 
0.4 mA shock (unconditioned stimulus, US). The shock onset began 29.5 s after the onset of the 
tone with inter-trial interval between 1-3 min. Post-test consisted of the same paradigm as pre-
test but was performed the day after training and the %FPS response for post-test was calculated 
using the formula as given above. If the mouse learned the response the %FPS score was 
expected to be amplified in the post-test. 
 
4.6. Brain dissection 
After 1 week acclimatization, adult db/db (11-12 week old) and age-matched lean control mice 
were euthanized by decapitation. The brains were removed and immediately immersed in ice 
cold 0.9% saline. The frontal cortex (FC) and brainstem (BS) were hand dissected. A mouse 
brain matrix (Ted Pella, Inc) was used to slice the remainder of the brain into 1 mm or 2 mm 
thick blocks rostral to the interaural line for three more brain regions: amygdala, hippocampus 






further dissection. The mouse brain stereotaxic coordinates (Paxinos and Franklin, 2008) were 
used as reference to dissect out specific brain regions using -20 
0
C ice blocks.  
4.7. Neurochemical studies 
4.7.a. Preparation of tissue samples 
All the brain regions were homogenized in 0.2N perchloric acid (300 μl) and centrifuged at 24 × 
4G at 4
0
C for 20 minutes. The aliquots of the supernatant were stored at -80 ºC until further 
analysis. 
 
4.7.b. Brain monoamine analysis 
As described previously (Macedo et al., 2004) with some modifications, monoamines and DA 
catabolite concentrations were measured in the specific brain regions of lean control, db/db and 
db/db + Rosiglitazone mice. Briefly, DA, 5-HT, NE, HVA and DOPAC were measured in FC, 
amygdala, hippocampus, hypothalamus and BS using reverse phase HPLC method. Detection 
was done using an LC-4B amperometric detector (Bioanalytical Systems Inc. BASi) optimized 
to 0.75 V. Samples were eluted through an ESA C18 column (80 X 4.6 mm X 3 μm, 
Chelmsford, MA). The mobile phase stock composed of: sodium phosphate (0.02 M), sodium 
citrate (0.05 M), ethylenediaminetetraacetic acid (EDTA, 3.4 M), diethylamine hydrochloride 
(0.01 M) and 1-octanesulfonic acid (0.001 M) was prepared in deionized water (up to 1 L). 
Phosphoric acid was used to adjust the pH to 3.1. Before analysis of sample aliquots, acetonitrile 
(12 ml), dimethylacetamide (5.5 ml) and 1-octanesulfonic acid (120 mg) were added to 250 ml 
volume of mobile phase stock. The mobile phase was run through the system having an 




Reference standard solution was prepared using known concentrations of DA, 5-HT, NE, HVA 
and DOPAC (Sigma-Aldrich, USA). The peaks obtained from reference standards were 
compared with the corresponding tissue sample neurotransmitter amplitudes to determine 
concentrations of monoamines and catabolites (ng/mg of wet tissue). Tissue homogenization did 
not alter monoamine or catabolite concentrations. The ratios of DA catabolites and 
neurotransmitter DA: HVA/DA and DOPAC/DA were calculated as an index of DA usage.  
4.8. Western blot analysis 
 Different isolated brain parts as mentioned above were homogenized on ice in phosphate 
buffered saline (PBS) containing protease inhibitor (Complete lysis M, Roche diagnostics, 
Germany). Homogenates were centrifuged (10,000 x g for 10 min, 4 
0
C) to remove cellular 
debris. Total protein content was determined in supernatant using bovine serum albumin (BSA) 
as a standard and BioRad reagent (BioRad, CA). 30 l of brain-region lysate was added to 30 μl 
sample loading buffer of composition: 8% SDS, 125 mmol/L Tris-HCl, pH-6.8, 20% glycerol, 
0.02% bromophenol blue, 100 mmol/L dithiothreitol and boiled for 6 minutes. Approximately 8-
12 μg protein was loaded to 8% SDS-PAGE gel for separation employing electrophoresis. 
Proteins on gel were then transferred (Bio-Rad transfer apparatus, CA) to a 0.2 μm PVDF 
membrane (Millipore, MA). The membranes were blocked for 1 hour with 10% non-fat milk 
made in 10 mM Tris buffered saline with Tween 20 (TBS-T) at room temperature (RT). For 
analysis, anti-tyrosine hydroxylase (AB152, Millipore, USA) was used made in 5% non-fat milk 
in TBS-T and incubated for 3-days at 4 
0
C to probe the membranes (dilution 1:1000). The 
membranes were washed with TBS-T buffer 3 times for 5 minutes at RT. Later, membranes were 
incubated with horse radish peroxidase (HRP) conjugated donkey anti-rabbit secondary antibody 




were detected using SuperSignal chemiluminescent substrate (Pierce, IL) and visualized in 
Fujifilm image analyzer (LAS-3000 Image Quant, CA). TH has a molecular weight of 62 kDa. 








5. Data analysis 
The results are presented as group means ± S.E.M. and analyzed using Graphpad Prism 5 
software. Data were analyzed by 2-way ANOVA test. The two variables for 2-way ANOVA test 
were ‘strain’ (db/db versus lean control) and ‘age’ of mice (juvenile versus adult). Bonferroni 
test was used for post-hoc comparisons. Unpaired Student t-test was used to analyze differences 
in body weight, food intake, water intake, % fat mass, % lean mass, % body water, blood glucose 
and plasma insulin concentrations. Neurochemistry and western-blot data was analyzed by 1-way 






6.1. Metabolic parameters 
As expected and shown in Table 1, the blood glucose concentrations of db/db mice were 
significantly higher compared to age-matched lean controls (p < 0.05, unpaired t-test). There was 
an age-dependent increase in blood glucose concentration of db/db mice (juvenile: 230.38±13.25 
mg/dL versus adult: 583.20±35.86 mg/dL). However, blood glucose concentrations of lean 
control mice remained fairly constant (p < 0.05). Food intake, water intake, plasma insulin and % 
fat mass of db/db mice were significantly increased compared to age-matched lean controls (p < 
0.05, unpaired t-test). However, percent lean mass and percent body water of db/db mice were 
significantly low compared to age-matched lean controls (p < 0.05, unpaired t-test). 
 
6.2. Behavioral tests 
6.2.a Depression-like behavior of db/db mice 
As shown in Fig. 1, juvenile as well as adult db/db mice were immobile for significantly more 
time than age-matched lean controls in the 6 min forced swim test [factor ‘strain’ F (1, 32) = 
83.22, p < 0.001]. There was no age-dependent significant change in duration of immobility in 
lean control as well as db/db mice (p > 0.05). 
 
6.2.b. Psychosis-like behavior of db/db mice 
Normal PPI was observed in juvenile db/db mice at both intensities of startle stimuli (Fig. 2; p > 
0.05). However, percent PPI in adult db/db mice was significantly lowered with respect to age-
matched lean controls with (70 dB + 85 dB) [factor ‘strain’ F (1, 36) = 9.705, p < 0.001] and (70 




dependent decrease in PPI response of db/db mice with (70 dB + 85 dB) startle stimuli [factor 
‘age’ F (1, 36) = 3.474, p < 0.05] but not with (70 dB + 100 dB) stimuli (p > 0.05). Three out of 
10 juvenile db/db mice also showed disruption of PPI for 70 dB + 100 dB (pre-pulse + pulse) 
startle stimuli, however, no change in PPI response of remaining 7 juvenile db/db mice of the 
group nullified this difference when compared with age-matched lean control group. 
 
6.2.c. Anxiolytic behavior of db/db mice 
In the elevated plus maze test, there was a significant increase in percent time spent in open arms 
(Fig. 3a) [factor ‘strain’ F (1, 31) = 7.785, p < 0.05, factor ‘age’ F (1, 31) = 16.73, p < 0.05)] and 
percent entries into open arms (Fig. 3b) [factor ‘strain’ F (1, 31) = 4.337, p < 0.05, factor ‘age’ F 
(1, 31) = 6.066, p < 0.05)] in juvenile and adult db/db mice as compared to age-matched lean 
controls. Moreover, db/db mice traveled about equivalent distances on open arms compared to 
age-matched lean controls (Fig. 3c) (p > 0.05). 
 
6.2.d. Hypo-locomotive and thigmotaxis behavior of db/db mice 
Both juvenile and adult db/db mice had significantly fewer activity counts for (a) basic 
movements and (b) fine movements compared to their age-matched lean controls in the open 
field test (Fig. 4a and b). Both strains also underwent a decrease in these measures over time. 
Two-way ANOVA showed a significant effect on basic movements [factor ‘strain’ F (1, 35) = 
74.17, p < 0.001; factor ‘age’ F (1, 35) = 52.94, p < 0.001] and fine movements [factor ‘strain’ F 
(1, 35) = 17.94, p < 0.05; factor ‘age’ F (1, 35) = 4.497, p < 0.01] of db/db mice compared to 
age-matched lean controls. During the 10 min test session, db/db and age-matched lean control 




thigmotaxis (p < 0.05). However, there was no difference in percent time spent in periphery 
between db/db mice and age-matched lean controls (p > 0.05) (Fig. 4c). 
 
6.2.e. Working memory test in db/db mice 
Percent Y-maze scores of juvenile as well as adult db/db mice were not statistically different 
from age-matched control littermates (p > 0.05; Fig. 5). There was a significant decrease in total 
number of Y-maze arms entries [factor ‘strain’ F (1, 33) = 12.91, p < 0.01] and alternation score 
due to decreased activity [factor ‘strain’ F (1, 33) = 7.469, p < 0.05] of adult db/db mice 
compared to age-matched control mice that led to no change in their percent Y-maze scores (p > 
0.05). 
 
6.3. Neurochemistry study 
6.3.a. Elevated HVA/DA ratio in the frontal cortex of db/db mice  
The neurotransmitter DA levels in the frontal cortex of db/db mice did not change compared to 
lean control mice (Fig. 6). However, there was a significant increase in the HVA levels in the 
frontal cortex of db/db mice compared to lean control mice (Fig. 7). These changes resulted into 
a significant increase in the frontal cortex HVA/DA ratio in db/db mice compared to lean 
controls (Fig. 9). Similar results were reported previously using type-2 diabetic female ob/ob 
mice [71]. 
 
6.3.b. Decreased HVA/DA and DOPAC/DA ratios in the 29mygdale of db/db mice  
In contrast to the frontal cortex, the HVA/DA ratios in amygdala were significantly decreased 




HVA were higher in db/db mice compared to lean controls (Fig. 6 and Fig. 7). A dramatic three-
fold rise in DA concentration (ng/mg of wet tissue) in amygdala of db/db mice was observed 
[Fig. 6, db/db (2.65 ± 0.60) versus lean control (0.86 ± 0.40)]. This was due to a significant 
decrease in DOPAC/DA ratio in amygdala of db/db mice compared to lean control (Fig. 10).  
However, no changes were seen in the HVA/DA ratios in the hippocampus, hypothalamus and 
brainstem regions of db/db mice compared to lean controls. Significant increases in DA and 
DOPAC concentrations were seen in brainstem (Fig. 6 and Fig. 8, respectively). However, the 
DOPAC/DA ratio remains unaffected. Measurement of DOPAC/DA in brain regions other than 
the amygdala did not show any significant changes (Fig. 10). 
6.3.c. Elevated NE and 5-HT levels in selective brain regions of db/db mice 
There was a significant rise in NE concentrations in the frontal cortex, hypothalamus and 
brainstem of db/db mice compared to lean controls (p < 0.05, Fig. 11). However, NE 
concentrations in the amygdala and hippocampus did not differ from lean controls (p > 0.05). 
The 5-HT concentrations were increased in frontal cortex, amygdala and brainstem of db/db 
mice compared to lean controls (p < 0.05, Fig. 12). In contrast, hippocampal and hypothalamic 5-
HT concentrations of db/db mice remained unchanged compared to lean controls (p > 0.05). 
 
6.4. Rosiglitazone treatment 
6.4.a. Rosiglitazone treatment controlled diabetic complications in db/db mice 
As shown in Fig. 13, rosiglitazone significantly lowered hyperglycemia of db/db mice over the 
5-week duration of treatment (p < 0.0001). This was also evident from plasma glucose 




significant on the blood glucose concentration of rosiglitazone treated db/db mice was not 
statistically different from age-matched lean control mice (p < 0.05; Fig. 13).  
6.4.b. Rosiglitazone treatment improved glucose utilization in the db/db mice 
In the intraperitoneal glucose tolerance test (GTT), 16 h fasted db/db mice showed significantly 
higher blood glucose values compared to age-matched lean controls (p < 0.0001; Fig. 14). In 
db/db mice blood glucose concentrations remain significantly elevated compared to lean control 
mice at all time-points during 120 min blood sampling (p < 0.0001; Fig. 14). This led to 
significantly higher area under the curve (AUC) in db/db mice compared to AUC for the lean 
control group (p < 0.0001; Fig. 14). In contrast, rosiglitazone treatment significantly improved 
glucose handling by db/db mice (p < 0.0001; Fig. 14).  Blood glucose concentrations of 
rosiglitazone treated db/db mice post-16 h fasting (0 Min) were not significantly different from 
fasted lean control mice (p > 0.05; Fig. 14). Moreover, the AUC post intraperitoneal glucose 
loading for rosiglitazone treated db/db mice was significantly decreased compared to db/db mice 
having no treatment (p < 0.0001; Fig. 14).  
 
6.4.c. Rosiglitazone reversed depression-like behavior of db/db mice 
As shown in Fig. 15, db/db mice were immobile for significantly longer in the FST compared to 
age-matched lean controls suggesting the presence of depression-like behavior (p < 0.05).  These 
results were in agreement with our previous findings (Fig. 1). Rosiglitazone treatment 
significantly decreased the duration of immobility of db/db mice in FST compared to db/db mice 
having no treatment (p < 0.05; Fig. 15). Thus, five weeks of rosiglitazone treatment to db/db 




significantly reduced the duration of immobility in FST in lean mice. However, this effect was 
independent of the glucose lowering potential of Rosiglitazone (Fig. 13).  
6.4.d. Rosiglitazone does not reverse hypolocomotive behavior of db/db mice 
As expected, db/db mice had significantly less activity counts for (a) basic movements and (b) 
fine movements compared to their age-matched lean controls in the open field test (p < 0.0001; 
Fig. 16). Rosiglitazone treatment did not reverse the hypolocomotive behavior of db/db mice. 
Both (a) basic movements and (b) fine movements of rosiglitazone treated db/db mice were not 
different compared to their age-matched db/db mice having no treatment (p > 0.05).  
 
6.4.e. Rosiglitazone does not reverse psychosis-like behavior of db/db mice 
Pre-pulse inhibition (PPI) behavior of 10-11 week old db/db mice was significantly disrupted 
compared to age-matched lean control mice (p < 0.05; Fig. 17) suggesting the presence of 
psychosis-like behavior. However, 5-week treatment with rosiglitazone failed to reverse 
psychosis-like behavior of db/db mice (p > 0.05; Fig. 17). Moreover, rosiglitazone significantly 
disrupted PPI behavior of lean control mice (p < 0.05). These results suggest that rosiglitazone 
treatment induced psychosis-like symptoms in lean control mice without affecting its blood 
glucose concentration per se. 
 
6.4.f. Rosiglitazone does not alter db/db mouse behavior in the fear potentiated startle test 
During the post-test, lean control mice had a potentiated fear response (p < 0.05; Fig. 18). In 
contrast, db/db mice did not have any such alterations in their behavior in FPS test (p > 0.05; Fig. 




mice that were on standard chow (p > 0.05). However, rosiglitazone treatment of lean control 
mice resulted in a potentiated fear response (p < 0.05; Fig. 18). 
 
6.5. Effect of rosiglitazone on abnormal DA metabolism pattern in db/db mouse brain 
6.5.a. Rosiglitazone normalized abnormalities in DA metabolism in the frontal cortex of 
db/db mice  
There was no change in the DA levels in the frontal cortex of db/db mice compared to lean 
control mice (Fig. 19). However, there was a significant increase in the frontal cortex HVA ratio 
in db/db mice compared to lean controls (p < 0.05; Fig. 20). This led to significant increase in the 
HVA/DA ratio in the frontal cortex of db/db mice compared to lean controls (Fig. 22). Similar 
results were reported previously using leptin-deficient ob/ob mice (Harris et al., 1998). 
Interestingly, the HVA/DA ratio in the frontal cortex of rosiglitazone-treated db/db mice was not 
different compared to age-matched lean controls (Fig. 22). The changes observed were due to 
restoration of frontal cortex HVA levels to normal (Fig. 19). Thus, rosiglitazone treatment 
significantly restored abnormal frontal cortex extraneuronal DA metabolism pattern to normal. 
However, rosiglitazone treatment failed to normalize intraneuronal DA metabolism pattern (i.e. 
DOPAC/DA ratio) in the frontal cortex of db/db mice. 
 
6.5.b. Rosiglitazone normalized abnormalities in DA metabolism in the 33mygdale of db/db 
mice  
In contrast to the frontal cortex, the HVA/DA ratios in amygdala of db/db mice were 
significantly decreased (Fig. 22, p < 0.05), a response consistent with decreased DA use. The 




19 and Fig. 20, respectively). In concordance of these changes, the DOPAC/DA ratios in the 
amygdala of db/db mice were also significantly decreased compared to lean control mice (Fig. 
23, p < 0.05). In the amygdala, DA and DOPAC levels were significantly increased. However, 
the DA increase was proportionally higher (~ 3 fold) compared to DOPAC (Fig. 19 and Fig. 21, 
respectively) that led to a significant decrease in the DOPAC/DA ratio (Fig. 23). Rosiglitazone 
treatment to normalize hyperglycemia and improve insulin sensitivity reversed these changes. 
Rosiglitazone treatment significantly restored DA, HVA and DOPAC levels in the amygdala to 
normal (Fig. 19, 20 and 21 respectively). 
There were no changes in the HVA/DA ratios in the hippocampus, hypothalamus and brainstem 
regions of db/db mice compared to lean controls. Significant increases in DA and DOPAC 
concentrations were seen in the brainstem (Fig. 19 and Fig. 21 respectively) but the DOPAC/DA 
ratio remained unaffected. Measurement of DOPAC/DA in brain regions other than the 
amygdala and brainstem did not reveal any significant changes (Fig. 23). Rosiglitazone 
administration normalized hyperglycemia and significantly increased DA and DOPAC levels in 
to the hypothalamus and brainstem of db/db mice (Fig. 19 and Fig. 21 respectively). However, 
these changes were proportionally similar. Therefore, the DOPAC/DA ratios remain unaffected 
(Fig. 23). The brainstem also had a significant elevation in HVA levels (Fig. 20) that accounted 
for a decline in the HVA/DA ratio (Fig. 22). In the hippocampus, rosiglitazone treatment 






6.5.c. Tyrosine hydroxylase expression pattern in db/db mice brain was similar to non-
diabetic lean control mice 
To examine if hyperglycemia and insulin resistance affects DA biosynthesis pattern, frontal 
cortex, amygdala and hypothalamus were analyzed for TH expression pattern (Fig. 24, Fig. 25, 
and Fig. 26 respectively). Compared to age-matched lean controls, TH expression pattern in 
these brain regions of db/db mice was not different (p > 0.05). Further, TH expression pattern in 
the hypothalamus of db/db mice were not significantly different compared to age-matched lean 
controls (p > 0.05; Fig. 26). These results were consistent with no differences in the DA 
metabolism in the hypothalamus of db/db mice compared to age-matched lean controls. 
 
6.5.d. Rosiglitazone normalized abnormalities in adrenal catecholamines in db/db mice 
To understand the impact of hyperglycemia and insulin resistance on adrenal catecholamine 
levels in db/db mice and effect of improving insulin sensitivity and normalizing hyperglycemia 
on them adrenal NE, DA and epinephrine (E) concentrations were determined. There was a 
significant increase in the adrenal NE, E and DA concentrations in db/db mice compared to age-
matched lean controls (Fig. 27). In contrast, normalization of hyperglycemia and improving 
insulin sensitivity using 5-week rosiglitazone treatment helped to restore db/db mice adrenal 






Type-2 diabetes significantly affects socio-economic status, quality of life and physical and 
mental health of diabetic patients. Neuropsychiatric disorders such as depression and 
schizophrenia are frequent co-morbid conditions in the diabetic population. The 
neuropsychological consequences of diabetes have been studied with reasonable detail in the 
clinical setting. However, there is still a scarcity of preclinical research supporting correlations 
between type-2 diabetes and such consequences. The current study attempted to provide 
experimental evidence for an interrelationship between type-2 diabetes and neuropsychological 
deficits using db/db mice. The principal findings of this study are: 
(1) Behavioral depression, age-related advancement of psychosis-like symptoms and anxiolytic 
behavior in db/db mice.  
(2) Abnormal DA metabolism patterns in the frontal cortex and amygdala of db/db mice that 
correlated with their behavioral deficits. 
(3) Rosiglitazone-induced reversal of depression- but not psychosis-like behavior and impaired 
emotional learning in db/db mice. 
(4) Restoration of the majority of changes observed in DA metabolism in the brains of db/db 
mice to normal post-rosiglitazone treatment. 
(5) Significant elevation in the adrenal catecholamine levels in db/db mice compared to age-
matched lean controls. Rosiglitazone treatment helped to restore them to normal. 
7.1. Neurobehavioral deficits in db/db mice 
Depression is the major co-morbid psychological disorder with diabetes (Anderson et al., 2001; 
Lin et al., 2004). We evaluated juvenile and adult db/db mice for behavioral depression using the 




duration of immobility compared to age-matched lean control mice suggesting the occurrence of 
depression-like symptoms in db/db mice. While the obesity of the adults may have impaired 
swimming ability, the swimming deficits in non-obese juveniles suggest that central nervous 
system mechanisms related to depression are the cause. Additionally, poor thermoregulation in 
db/db mice can also confound immobility duration in FST. However, Trayhurn reported similar 
diurnal rhythms in body temperature of db/db mice compared with control mice at 23 °C 
(Trayhurn, 1979). We used a similar temperature range (23–25 °C) for FST. In contrast to rats 
that generally require two-trial FST, one-trial is adequate to produce consistent immobility 
scores using mice in FST (Borsini and Meli, 1988; Cryan and Lucki, 2000; Lucki et al., 2001). 
The probability of depression in diabetic patients is approximately double that of those without 
diabetes (Anderson et al., 2001). Behavioral despair in diabetic patients can lead to apathy 
towards self-care regimens such as regular physical exercise, dietary habits, cessation of smoking 
and towards medication for diabetes (Lin et al., 2004). Diabetic patients with comorbid 
depression are reported to have double the probability of cardiac risk factors like smoking, 
obesity, sedentary lifestyle etc (Katon et al., 2004). Recently Hirano and colleagues reported a 
decrease in circulating plasma leptin concentrations and depression-like symptoms in 
streptozotocin-induced diabetic mice (Hirano et al., 2007). Interestingly, treatment of these 
diabetic mice with leptin reversed the depression-like behavior in the tail suspension test (TST), 
a model for depression. In view of the mutation in leptin receptors (LRb) in db/db mice and an 
antidepressant-like effect of leptin in a mouse model for diabetes, behavioral depression 
observed in db/db mice may be the outcome of impaired leptin signaling. Leptin treatment 
restores the preference for sucrose consumption in rodents subjected to chronic stress and 




(Katz, 1982; Lu et al., 2006). Further, systemic leptin treatment is reported to lower immobility 
in FST and TST in rodents, an indicator of antidepressant-like effect of leptin that was not 
dependent upon stimulation of motor behavior. Thus, leptin can serve as a potential 
neurobiological substrate for the treatment of depression (Lu et al., 2006). Several research 
groups reported expression of leptin receptors in serotonergic raphe nuclei (Finn et al., 2001) and 
dopaminergic ventral tegmental area and substantia nigra (Figlewicz et al., 2003). Collin and co-
workers reported a fall in serotonin transporter mRNA expression in raphe nuclei of functional 
leptin deficient ob/ob mice (Collin et al., 2000). Leptin increases production of serotonin and its 
biotransformation product, 5-HIAA in the forebrain (Calapai et al., 1999). Thus, it is plausible 
that leptin may interact with monoaminergic neurons involved in the pathophysiology of 
depression and related disorders by modulating their firing pattern and downstream signaling 
mechanisms in a manner that may lead to depression in humans and to the behavioral deficits in 
db/db mice. 
We used PPI of startle to evaluate age-dependent progression of psychosis-like symptoms in 
db/db mice (Fig. 2). While juvenile db/db mice did not differ from age-matched lean controls in 
terms of percent PPI scores when subjected to a series of randomly presented pre-pulse plus 
pulse (70 dB + 85 dB and 70 dB + 100 dB) startle stimuli trials, adult db/db mice experienced 
significant disruption of PPI behavior with respect to age-matched lean controls. Such disruption 
of PPI behavior in adult but not in juvenile db/db mice signifies age-dependent progression of 
psychosis-like behavior in this murine model for type-2 diabetes. Three out of 10 juvenile db/db 
mice also showed psychosis-like behavior, which may indicate that this is the age at which 




psychotic subjects. Disruption of PPI is the hallmark symptom to confirm psychosis-like 
symptoms and it is rare to ever have a disruption in a normal animal. 
Comorbid type-2 diabetes is reported to impair the physical as well as mental health status of 
adult schizophrenic patients compared to non-diabetic schizophrenics (Dickinson et al., 2008). 
The emergence of new-onset diabetes was reported in schizophrenic patients following initiation 
of atypical antipsychotic medications (Lambert et al., 2006; Ramaswamy et al., 2006; van 
Winkel et al., 2008). Hyperglycemia and insulin resistance was also reported in mice that were 
on chronic antipsychotic treatment (Dwyer and Donohoe, 2003). Current clinically proven 
medications for psychosis may not prove a good strategy to treat co-occurring psychotic 
symptoms in the diabetic population because they may further complicate existing diabetic 
phenotypes. Recently van Nimwegen and co-workers showed that antipsychotic naive 
schizophrenics also have hepatic insulin resistance compared to non-schizophrenic controls. 
Such increased propensity towards insulin resistance in schizophrenics may be the outcome of 
metabolic abnormalities (van Nimwegen et al., 2008). These findings hint toward a bidirectional 
link between diabetes and schizophrenia. 
We observed db/db mice to be less anxious than age-matched lean controls in the elevated plus 
maze test (Fig. 3). Juvenile as well as adult db/db mice spent significantly more time on the open 
arms compared to age matched lean controls. db/db mice also showed a significant increase in 
percent open arms entries compared to age-matched lean controls. Both age-group db/db mice 
traveled equal distances on open arms compared to age-matched lean controls suggesting that the 
observed increase in time spent into open arms by db/db mice is not affected by their hypo-




about leptin’s role in anxiety behavior is ambiguous. Asakawa and co-workers reported that 
leptin treatment can ameliorate anxiety-like behavior of ob/ob mice (Asakawa et al., 2003). On 
the other hand, Buyse and colleagues reported decreased open arm exploration in the elevated 
plus maze test after intraperitoneal leptin treatment in diet-restricted rats (Buyse et al., 2001). In 
contrast, Suomalainen and Mannisto reported that higher doses of leptin (10 and 20 mg/kg) 
failed to affect anxiety behavior in ad libitum fed mice (Suomalainen and Mannisto, 1998). Also, 
in spontaneously diabetic INS2
Akita
 mice, Asakawa and colleagues reported anxiety-like behavior 
using the elevated plus maze test (Asakawa et al., 2007). Labad and colleagues recently have 
shown that depression but not anxiety is associated with type-2 diabetes (Labad et al., 2010). 
Results of anxiety and depression screening of db/db mice are consistent with this clinical report 
showing the presence of depression but not anxiety. In contrast to this, high anxiety scores 
(Collins et al., 2009) and an increased prevalence of generalized anxiety disorder was reported in 
type-2 diabetic patients relative to non-diabetic adults elsewhere (Fisher et al., 2008). Clinical 
studies evaluating anxiety levels in type-2 diabetic patients led to conflicting outcomes. 
Exploring the biological mechanisms that govern anxiolytic behavior of db/db mice may help to 
understand why there are differences in some but not all neuropsychological deficits with type-2 
diabetes. 
In the open field test, db/db mice undergo a decrease in basic movements (quantified by IR beam 
interruptions due to more body movements in the open field) and fine movements (IR beam 
interruptions due to fine movements such as head-twitching, grooming etc) compared to age-
matched lean controls (Fig. 4). These results are in agreement of our previous research report 
(Senador et al., 2009) and others (Laposky et al., 2008; Stranahan et al., 2009). Laposky and 




while the present study investigated locomotor behavior of much younger (5–6 weeks) db/db 
mice. Similar changes in locomotor behavior of juvenile db/db mice were reported by Hesse and 
co-workers (Hesse et al., 2009). We evaluated db/db mice for basic movements due to whole 
body movements as well as fine movements resulting from head-twitching, grooming etc. Hypo-
locomotion is the hallmark feature of several psychiatric disorders like Parkinson’s disease, 
Huntington chorea, antipsychotic-induced pseudoparkinsonism etc. While some have argued that 
decreased locomotor activity in the open field test may account for increased duration of 
immobility in FST, others have observed no correlation between locomotor activity and 
performance of mice in FST (Collin et al., 2000; Crawley et al., 1997). Increased immobility in 
FST as well as decreased locomotor activity was reported in ob/ob mice (Collin et al., 2000). 
Further, clinical studies indicated comorbidity of depression with hypo-locomotive disorders 
such as Parkinsonism (Papapetropoulos et al., 2006). If a decrease in locomotor activity is 
causing increased immobility time in the forced swim test, it should also reduce the distance 
traveled on open arms in the elevated plus maze. However, there was no reduction in the db/db 
mice compared to age-matched lean controls in distance traveled. We also believe that the open 
field test is not a behavioral model to test depression-like symptoms unless the animals are 
olfactory bulbectomized. It is most appropriately used to reflect deficits in motor behavior and to 
test partial anxiety than depression of mice with intact olfactory bulbs. Thus, depressive-
symptoms can also be observed in hypo-locomotive individuals. The use of alternative models 
such as learned helplessness, sucrose preference test or TST that mimics depression-like 
symptoms may further strengthen the evidence for the presence of depressive symptoms in this 
mouse strain. Unfortunately the sucrose consumption test requires an extensive amount of time 




evaluation of age-related changes in behavior. Previous reports suggest that TST is not the ideal 
test for mice with C57 genetic background (like db/db mice) that have a tendency to climb on the 
tail (Mayorga and Lucki, 2001). Further, TST, like FST, can also depend on motor activity 
(Cryan and Lucki, 2000). Like lean controls, db/db mice also exhibited thigmotaxis behavior—a 
tendency of animals to stay in proximity of support while traveling. This is indicative of a 
normal response to the low stress environment of an open arena. Stranahan and colleagues also 
showed similar tendency of db/db mice to spend less time in the center arena. However, they also 
have reported significant difference in percent time in center arena between db/db mice and 
control mice (Stranahan et al., 2009). 
Cognitive deficits are commonly seen in obese and diabetic rodents (Li et al., 2002) and are also 
prevalent in type-2 diabetic patients (Gispen and Biessels, 2000). Diabetic obese rodents have 
impaired spatial memory task performance in the Morris water maze test (Li et al., 2002). We 
tested db/db mice for their working memory rather than spatial memory performance. Both age-
group db/db mice did not show signs of impairment of working memory in Y-maze test 
compared to age-matched lean control mice (Fig. 5). While the frontal cortex is the anatomical 
site for working memory, the hippocampus’s role as the regulator for spatial memory functions is 
well documented (Bohlen und et al., 2006; Courtney et al., 1998). Recently, Stranahan and 
colleagues reported diabetes-induced detrimental effects on hippocampal neurons, impaired 
recovery from hippocampal neuronal defects post-calorie restriction and increased energy 
expenditure in insulin-resistant and leptin-receptor mutated db/db mice (Stranahan et al., 2009). 
Further, leptin can alter neuronal dendrite morphology (O'Malley et al., 2007). Elevations in 
corticosterone levels (Stranahan et al., 2008) as well as reduced hippocampal brain-derived 




for diabetes-related cognitive deficits. Ohta and colleagues using conditioned taste aversion 
(CTA) learning test showed that impaired downstream signaling due to the mutation in leptin 
receptors in db/db mice had no effect on acquisition of CTA learning but promoted faster 
extinction (Ohta et al., 2003). Yamamoto suggested the parabrachial nucleus, amygdala, insular 
cortex, supramammillary nucleus, nucleus accumbens, and ventral pallidum as possible 
anatomical sites for CTA learning in rats (Yamamoto, 2007). Li and colleagues reported 
compromised spatial memory performance in the Morris water maze test (Li et al., 2002). db/db 
mice may have intact working memory as evident from Y-maze test results but poor spatial 
memory performance and faster extinction of CTA points to anatomical specificity in memory 
deficits. 
Apart from leptin and insulin resistance (de la Monte et al., 2009), hormones like ghrelin (Sun et 
al., 2007) and neurotransmitters e.g. norepinephrine (Garris, 1988; Garris, 1995) could be other 
mechanisms that may govern type-2 diabetes-linked CNS dysfunctions. Evidence suggests that 
leptin can restore normal glucose levels (Pelleymounter et al., 1995) and improve insulin-
sensitivity of target organs (Levin et al., 1996; Lin et al., 2002). In contrast, long-term 
hyperglycemia lowers leptin levels (Moriya et al., 1999). Thus insulin and leptin may have 
similar mechanisms and maintain close temporal synchronism. Although mutations in leptin 
receptors are not observed clinically, db/db mice could be an important experimental tool to 
investigate the possible involvement of leptin in diabetes related insulin resistance and comorbid 
complications. Recently, Schwartz and Bahn reviewed possible application of altered proteins 
and metabolites identified in schizophrenic brain cerebrospinal fluid (Schwarz and Bahn, 2008). 
Investigations for such schizophrenia-specific biomarkers in type-2 diabetic brains may unravel 




view of resistance to insulin (severe hyperinsulinemia) and leptin (mutation in leptin receptor 
LRb isoform), pharmacological manipulation of db/db mice with exogenous insulin or leptin to 
correct observed behavioral depression and psychosis-like symptoms do not seem to have a 
convincing rationale.  
In conclusion, this is the first study to report behavioral depression, psychosis-like 
symptoms and anxiolytic behavior in db/db mice strain. Also, db/db mice were hypo-locomotive; 
exhibited normal thigmotaxis and no impairment of working memory. Thus, db/db mice showed 
the presence of select group of neuropsychological deficits. The db/db mice could be used as a 
model to study type-2 diabetes-induced depression and psychosis. Investigations to find 
biochemical and neurobiological markers governing these deficits may help to improve our 
understanding about interrelationships between diabetes and comorbid CNS disorders. 
7.2. Impact of type-2 diabetes on the brain dopamine metabolism in db/db mice 
Although clinical studies suggest an increased prevalence of neuropsychiatric disorders in 
type-2 diabetic patients, the primary mechanisms for such co-morbidities are poorly understood. 
There is a need to study the neurochemical basis of such co-morbidities employing type-2 
diabetic animal models to increase our understanding of their interrelationships. Classic theories 
of major neurobehavioral disorders suggest changes in the usage of dopamine (DA) in specific 
brain regions (Howes and Kapur, 2009; Wise, 2008). DA is one of the key neurotransmitters that 
is involved in the pathophysiology of schizophrenia (Howes and Kapur, 2009) and depression 
(Dunlop and Nemeroff, 2007). Based on this, the db/db mouse brain regions that were selected 
for analysis of changes in DA turnover receive DA neuronal projections from  distinct 




significance: e.g. mesolimbic-mesocortical, nigrostriatal, periventricular, incerto-hypothalamic 
and descending DAergic systems (Farooqui et al., 1994). The principal finding of the 
neurochemical experiments is that insulin resistance and hyperglycemia in db/db mouse 
differentially influences DA turnover in different brain regions. To our knowledge, this is the 
first evidence for elevated HVA/DA ratios in db/db mouse brain frontal cortex and this is 
consistent with our recent findings of disrupted pre-pulse inhibition behavior in this strain 
analogous to psychosis-like symptoms (Sharma et al., 2010a; Sharma et al., 2010b). The 
observed elevation in HVA/DA ratio in db/db mice frontal cortex was the result of an increase in 
the HVA concentration, which is only formed by extra-neuronal biotransformation. The frontal 
cortex receives neuronal projections from the mesolimbic-mesocortical DAergic system and DA 
neurotransmission in this brain region plays a distinctive role in the modulation of the startle 
reflex as measured by pre-pulse inhibition of the reflex (Lazar et al., 2008; Mehler-Wex et al., 
2006; Nakasato et al., 2008). The increased HVA concentration in the frontal cortex of db/db 
mice parallels that of post-mortem increases in frontal cortex HVA levels in schizophrenic 
patients compared to normal brains. (Bacopoulos et al., 1979; Davis et al., 1991). No changes in 
TH expression pattern were seen in the frontal cortex of db/db mice compared to age-matched 
lean controls. Thus, abnormal DA metabolism pattern in this brain region of db/db mice may be 
related to changes in the enzymatic activity of DA metabolizing enzymes and/or altered neuronal 
firing. 
The amygdala is an important component of the mesolimbic DAergic system composed 
of neuronal projections from the ventral tegmental area (VTA), retrorubral field and substantia 
nigra pars compacta (SNpc) in the mesencephalon to the amygdala, nucleus accumbens and 




(Fadok et al., 2009) and pre-pulse inhibition (Stevenson and Gratton, 2004). In the present study, 
we observed significantly increased DA and HVA concentrations in db/db mice amygdala 
compared to lean controls. However, a greater increase in DA than HVA was observed (HVA: 
51% increase versus DA: 231% increase). The DOPAC concentrations in the amygdala of db/db 
mice remained unchanged compared to lean controls. Altogether, these changes led to a 
significant decrease in amygdala HVA/DA and DOPAC/DA ratios. Further, there were no 
changes in the TH expression pattern in the amygdala of db/db mice compared to age-matched 
lean controls. Thus, an abnormal DA metabolism pattern in the amygdala of db/db mice may be 
related to changes in the enzymatic activity of DA metabolizing enzymes. Nonetheless, such 
large increases in both the parent transmitter and its extracellular catabolite warrant further 
investigation for expression of DA metabolizing enzymes and neuronal firing patterns in this 
brain region.  
 The hippocampus receives mesolimbic DAergic projections and is involved in cognitive 
functions and pre-pulse inhibition behavior (Ellenbroek et al., 2002). We did not observe any 
significant differences in DA, HVA or DOPAC concentrations in the hippocampus. This led to 
no changes in HVA/DA and DOPAC/DA ratios in the hippocampus of db/db mice compared to 
lean control mice.  
 The hypothalamus receives DAergic projections from the incerto-hypothalamic DAergic 
pathway with the important function in regulation of feeding behavior. The BS also receives 
descending DAergic neuronal projections yet other cell bodies. We did not observe any 
significant differences in HVA/DA and DOPAC/DA ratios in hypothalamus or BS of db/db mice 




region and DAergic-pathway specific, as would be observed in specific changes in either a 
subset of DA cell bodies or in the neuronal input to these cell bodies.  
 This is the first experimental evidence of altered DA neurotransmission in distinct brain 
regions of db/db mice. In clinical practice, the interrelationship between type-2 diabetes and the 
DAergic systems is gaining increased attention. Recently, the FDA approved the DA receptor 
agonist, bromocriptine, for treatment of type-2 diabetes to improve glycemic control. The current 
literature also suggests crosstalk between DA receptors and insulin secretion (Contreras et al., 
2008a; Garcia-Tornadu et al., 2010b). In addition to DA, leptin (Venkatasubramanian et al., 
2010) and insulin (Guest et al., 2011) implicated in development of neuropsychiatric disorders. 
Research examining the role of such novel candidates in type-2 diabetes related CNS 
dysfunctions may help to explain mechanisms governing behavioral and neurochemical 
alterations in db/db mice.  
7.3. Impact of improved insulin sensitivity and normalized hyperglycemia on 
neurobehavioral deficits in db/db mice 
We observed depression- and psychosis-like behaviors in db/db mice (Fig. 1 and Fig. 2, 
respectively). These findings were in agreement with clinical findings of increased prevalence of 
depression (Anderson et al., 2001) and schizophrenia (Mukherjee et al., 1996; Mukherjee et al., 
1989) in type-2 diabetic population. To extend our understanding of the mechanisms underlying 
type-2 diabetes associated neurobehavioral deficits, we treated db/db mice with the insulin 
sensitizer, rosiglitazone. The principal findings of this study are: insulin resistance and related 
hyperglycemia are the underlying mechanisms for depression but not psychosis-like behavior of 




A meta-analysis of clinical studies concludes that depression in the diabetic population is linked 
to hyperglycemia (Lustman et al., 2000). Drugs targeting insulin resistance and hyperglycemia 
such as pioglitazone have beneficial effects on brain functions in humans and in experimental 
models (Thal et al., 2011). Pioglitazone injection into C57BL6 mice post-cortical injury dose-
dependently reduced brain damage and inflammation (Thal et al., 2011). Rosiglitazone decreases 
the severity of symptoms in insulin-resistant depressed patients (Rasgon et al., 2010). Based on 
these studies, we subjected juvenile db/db mice to 5-weeks of rosiglitazone treatment and studied 
its impact on the neurobehavioral deficits. Rosiglitazone normalized hyperglycemia to age-
matched lean controls (Fig. 13). Moreover, rosiglitazone treated db/db mice handled glucose 
more efficiently than those without treatment (Fig. 14) indicating improved insulin sensitivity.  
Rosiglitazone treated db/db mice exhibited a significant increase in the duration of 
mobility in the forced swim test. Thus, rosiglitazone treatment helped to reverse depression-like 
behavior of db/db mice (Fig. 15). However, the motor behavior of rosiglitazone treated db/db 
mice was not different from db/db mice that were on standard chow (Fig. 16). In the open field 
test, basic movement and fine movement of rosiglitazone treated db/db mice were not 
significantly different compared to db/db mice fed with standard chow. Thus, the rosiglitazone-
induced decrease in immobility time in the FST was independent of changes in locomotor 
activity. Eissa Ahmed and co-workers reported antidepressant-like effect of rosiglitazone in rats 
and mice (Eissa Ahmed et al., 2009). However, they used normal non-diabetic strains for their 
study. We observed a similar antidepressant-like effect of rosiglitazone in lean control mice that 
was independent of its antihyperglycemic effect. Administration of the PPAR receptor agonist 
pioglitazone decreased the duration of immobility in mouse FST and prior administration of a 




PPAR receptor activation may mediate antidepressant-like effects of rosiglitazone in lean 
controls independently of its effect on blood glucose. Neuron-specific PPAR receptor knockout 
and high fat diet mice underwent very little improvement in glucose metabolism after 
rosiglitazone (Lu et al., 2011), suggesting role for central PPAR receptors in hepatic insulin 
sensitivity. Thus, we speculate that diabetes related hyperglycemia and insulin resistance at least 
partially contribute to the development of depression-like behavior in db/db mice.  
To study the effect of normalizing hyperglycemia and improving the insulin sensitivity of 
psychosis-like behavior of db/db mice, we used the pre-pulse inhibition (PPI) of startle test. As 
shown in Fig. 2, db/db mice had an age-dependent advancement of psychosis-like behavior. A 
separate group of adult db/db mice also showed disruption of PPI behavior compared to age-
matched lean controls (Fig. 17) thus replicating the finding of psychosis-like behavior. In 
contrast to its antidepressant-like effect in FST, rosiglitazone treatment did not restore PPI 
behavior in db/db mice (Fig. 17). Thus, controlling hyperglycemia and insulin resistance failed to 
overcome the psychosis-like behavior of db/db mice. However, rosiglitazone significantly 
disrupted PPI behavior of lean control mice (Fig. 17). A growing amount of evidence suggests an 
important role of leptin in psychiatric disorders (Sentissi et al., 2008; Zupancic and Mahajan, 
2011). Clinical studies indicate that antipsychotic drugs increase systemic leptin levels (Sentissi 
et al., 2008) and this may be the crucial mechanism for their antipsychotic action. Rosiglitazone 
treatment lowers systemic leptin levels in lean control mice (Holguin et al., 2007) and this may 
be the mechanism for the induction of psychosis-like behavior in lean controls. Maeda and co-
workers used a psychostimulant-induced behavioral sensitization model to study the effect of 
PPAR receptor agonists on psychosis behavior in mice (Maeda et al., 2007). Methamphetamine-




psychosis behavior. PPAR agonists reversed methamphetamine withdrawal symptoms but not 
the development of behavioral sensitization to methamphetamine in mice (Maeda et al., 2007). 
Thus, PPARreceptors regulate behavioral sensitization to methamphetamine in mice. db/db 
mice are refractory to leptin treatment because of the mutation in the functional leptin receptor 
isoform LRb (Chen et al., 1996). Perhaps, alternative mechanisms like impaired leptin signaling 
may be the dominant mechanism governing psychosis-like behavior of db/db mice. Evaluation of 
psychosis-like behavior in the alternative mouse strain like ob/ob mice that responds to leptin 
treatment may help to answer this question. Further investigations for changes in schizophrenia-
specific diagnostic markers, as reported elsewhere (Schwarz and Bahn, 2008), in type-2 diabetic 
brains may help to unravel mechanisms for psychosis-like behavior in db/db mice.  
Stress may be an important contributing factor to the development of diabetes and co-
morbid disorders (Castaneda et al., 2011; Trento et al., 2010). There is impaired glucose 
tolerance in a mouse model for post-traumatic stress disorder (PTSD) (Castaneda et al., 2011). In 
a recent cross-sectional study, there was a strong association between lifetime PTSD symptoms 
in low-income patients and > 7% HbA1C levels (Miller et al., 2011). Alternatively, PTSD is a 
risk factor for the development of diabetes (Weiss et al., 2011). Based on these findings, we 
evaluated db/db mice for PTSD-like behavior using the fear-potentiated startle (FPS) test.  The 
FPS test is a neurobehavioral model involving fear conditioning in which a neutral stimulus is 
paired with an aversive event in which the animal exhibits an exaggerated startle response in the 
presence of the conditioned stimulus alone (Davis, 1993; Maren, 2001a; Maren, 2001b). 
Abnormalities in the amygdala DA neurotransmission can interfere with fear conditioning 
response. db/db mice showed impairment in acquiring FPS compared to age-matched lean 




metabolism in the amygdala of db/db mice (Fig. 22 and Fig. 23). However, controlling 
hyperglycemia by means of rosiglitazone treatment did not alter impaired FPS learning behavior 
of db/db mice. Rosiglitazone treatment did not affect blood glucose concentration of lean control 
mice (Fig. 13) but it caused impairment in their FPS learning behavior (Fig. 18). Thus, 
Rosiglitazone treatment itself may be a risk factor in heightening PTSD symptoms.  
 Thus, early pharmacological intervention to improve insulin sensitivity and normalize 
hyperglycemia qualifies to overcome type-2 diabetes related selective neurobehavioral deficits 
such as depression. Further, glutamate (Widerlov et al., 1988), dopamine (Davis et al., 1991; 
Dunlop and Nemeroff, 2007), serotonin (Butler and Meegan, 2008) and neuropeptides (Yasuhara 
and Chaki, 2010) are the dominant mechanisms orchestrating neuropsychiatric disorders. Such 
alternative mechanisms may contribute to type-2 diabetes related neurobehavioral deficits. 
Recently, the neurotransmitter dopamine was identified as having a role in type-2 diabetes and 
related complications (Barber et al., 2003; Chen and Yang, 1991; Cincotta et al., 1997; Contreras 
et al., 2008b; Fetissov et al., 2002; Figlewicz et al., 1996; Gainetdinov, 2007; Garcia-Tornadu et 
al., 2010a). Thus, deficiencies in dopamine signaling may contribute to the progression of type-2 
diabetes.  
7.4. Impact of improved insulin sensitivity and normalized hyperglycemia on abnormalities 
in brain DA metabolism pattern in db/db mice 
To test the hypothesis that hyperglycemia and insulin resistance are the mechanisms for 
abnormal DA metabolism in db/db mouse brain, mice were subjected to 5 weeks of rosiglitazone 
treatment. Rosiglitazone treatment reduced frontal cortex HVA levels to those that were not 
different from age-matched lean controls. This accounted for restoration of the HVA/DA ratio to 




DA, HVA and DOPAC levels in the amygdala to those of age-matched lean controls (Fig. 19, 20 
and 21, respectively). Thus, we speculate that hyperglycemia and insulin resistance might be the 
causative mechanisms for abnormal DA metabolism pattern in the frontal cortex and amygdala 
of db/db mice. In the hippocampus, rosiglitazone treatment significantly reduced hippocampal 
DOPAC levels and therefore DOPAC/DA ratio suggesting rosiglitazone-induced decreased DA 
usage in this brain region. Further, rosiglitazone treatment significantly increased DA and 
DOPAC concentrations in the hypothalamus. These changes accounted for decreased HVA/DA 
and DOPAC/DA ratios in this brain region of db/db mice. Thus, the type-2 diabetes-induced 
changes in DA function are brain-region and dopaminergic pathway specific, as would be 
observed in specific changes in either a subset of DA cell bodies or in the neuronal input to these 
cell bodies. In the brainstem, rosiglitazone treatment caused lowering of HVA/DA and 
DOPAC/DA ratios in db/db mice compared to lean controls. This effect was observed due to 
rosiglitazone-induced increase in DA, HVA and DOPAC levels in the brainstem of db/db mice. 
Thus, rosiglitazone treatment increased brainstem dopaminergic activity. 
 
7.5. Type-2 diabetes related alterations in the NE and 5-HT concentrations in selected 
brain regions of db/db mice. 
In addition to DA, the role of NEergic and 5-HTergic systems in neuropsychological deficits is 
well documented (Blows, 2000a; Blows, 2000b). The central NE system has two major neuronal 
projections. One of them has origin in the later ventral tegmental NEergic cell bodies with 
projection to the forebrain and plays a crucial role in aggressive and feeding behaviors (Bhatia et 
al., 1997; Hoebel et al., 1989). The second NEergic system originates from the locus coeruleus 




biological functions. NE transporters are the mechanism for termination of synaptic NE action in 
the brain. One recent study suggested that aberrations in downstream insulin signaling proteins, 
normally observed in diabetes, significantly decreases expression of NE transporters in the brain 
(Robertson et al., 2010). Consistent with this, we observed significantly increased NE 
concentrations in FC, hypothalamus and BS regions of db/db mice compared to lean controls in 
agreement with previous studies (Garris, 1990; Garris, 1995). NEergic hyperactivity in db/db 
mouse brain is consistent with depression-like behavior of this mouse strain (Sharma et al., 
2010a; Sharma et al., 2010b). Clinical and preclinical studies also support NEergic hyperactivity 
in depression (Gold and Chrousos, 2002; Simson and Weiss, 1988a; Simson and Weiss, 1988b). 
Further, NE in the FC plays a critical role in mesoaccumbens DA release and reward (Ventura et 
al., 2003). Hypothalamic NE is implicated in regulation of neural circuits involved in eating 
disorders (Shor-Posner et al., 1985) while the LC nucleus has an important role in depression and 
anxiety. Increase in hypothalamic NE concentration was considered as a crucial mechanism for 
diabetes related neuroendocrine abnormalities such as hyperphagic and polydypsic behavior 
(Barber et al., 2003). Thus, elevated NE levels in the selective brain regions of db/db mice 
corroborated with their neurobehavioral deficits. 
5-HT within the FC is suggested to modulate cognition and emotion (Zhong et al., 2008). 
Selective 5-HT depletion in the FC can produce a behavioral phenotype similar to obsessive-
compulsive disorder and schizophrenia (Clarke et al., 2005). We observed an elevated 5-HT 
concentration in FC even though they exhibited psychosis-like symptoms. Although conflicting 
roles for 5-HT in FC are reported, we speculate that diabetes-related psychosis-like symptoms 
may be related to a deficit in 5-HT release causing elevated levels.  Alternatively, the levels are 




experiments would be necessary to resolve this question. The amygdala receives large 5-HTergic 
innervations from the dorsal raphe nucleus of the BS and activation of this nucleus elevates 5-HT 
release in the amygdala (Chaouloff, 2000). We observed a significant rise in the 5-HT 
concentration in the amygdala of db/db mice compared to lean controls. The BS contains a 
cluster of 5-HTergic neurons with diverse physiological functions that includes wakefulness, 
thermoregulation and regulation of blood pressure (Brodie and Shore, 1957). Although 5-HT is 
distributed throughout in the brain, its highest concentration is in the BS where it acts as a 
mediator for certain subcortical centers. Thus, elevated 5-HT concentrations in the BS of db/db 
mice may participate in attention deficits, poor thermoregulation and poor blood pressure 
regulation. No changes in hypothalamic 5-HT concentrations were seen in db/db mice compared 
to lean controls which is in agreement with previous a report using same mouse strain (King and 
Rohrbach, 1990). It would be interesting to pursue future studies that may address the 
neuropathological significance of differential alterations in NE and 5-HT function instead of just 
their concentrations in discrete brain regions of db/db but not lean control mice.  
 
7.6. Type-2 diabetes related alterations in the adrenal catecholamines in db/db mice 
Long-term stress management in type-2 diabetic patients has been shown to improve glycemic 
control in clinical setting (Surwit et al., 2002). Further, diabetes has long been considered as a 
stress disorder (Golbidi et al., 2011). To understand the impact of hyperglycemia and insulin 
resistance on adrenal catecholamine levels in db/db mice and the effect of improving insulin 
sensitivity and normalizing hyperglycemia on them adrenal NE, DA and epinephrine (E) 
concentrations were determined. There was a significant increase in the adrenal NE, E and DA 




hyperglycemia and improving insulin sensitivity using 5-week of rosiglitazone treatment helped 
to restore db/db mice adrenal catecholamine levels to normal (Fig. 27). Hypothalamic DA, NE 
concentrations and TH expression of db/db mice were not statistically different compared to age-
matched lean controls (Fig. 6 and Fig. 11). A compelling amount of evidence supports a role of 
stress-induced sympathetic system over-stimulation in the pathophysiology of type-2 diabetes 
(Surwit and Feinglos, 1988; Surwit and Schneider, 1993) consistent with the alleviation of stress 
following administration of the anti-hyperglycemic and insulin sensitizer rosiglitazone (Yao et 
al., 2009). Thus, we speculate that diabetes might serve as a stress and trigger overstimulation of 
adrenal sympathetic tone leading to increased adrenal catecholamine levels. Approaches to 
improve insulin sensitivity and normalize hyperglycemia may help to overcome diabetes related 






The present study provides experimental evidence for type-2 diabetes associated behavioral and 
neurochemical deficits using db/db mice. The major findings of this dissertation report are: 
(1) Behavioral despair, age-dependent progression of psychosis-like symptoms and anxiolytic 
behavior in db/db mice.  
(2) Neurochemical deficits in db/db mouse brain such as abnormal DA metabolism patterns in 
the frontal cortex and amygdala that correlated with their behavioral deficits. 
(3) Insulin sensitizer-induced reversal of behavioral despair- but not psychosis-like behavior and 
impaired emotional learning in db/db mice. 
(4) Restoration of the majority of abnormalities in DA metabolism in the brains of db/db mice to 
normal by long-term management of hyperglycemia and insulin resistance. 
(5) Significant elevation in the adrenal catecholamine levels in db/db mice compared to age-
matched lean controls. Rosiglitazone treatment helped to restore it to normal. 
 Thus, insulin resistance and hyperglycemia in db/db mice may be at least part of the 
underlying mechanisms for some but not all type-2 diabetes associated neurobehavioral deficits. 
Mechanisms other than those mentioned above may contribute for behavioral abnormalities such 








9. Prospective studies 
Leptin 
Leptin is an adipose tissue derived hormone. A high leptin concentration acts within the brain 
to signal satiety via hypothalamic LRb and boosts energy expenditure (Elmquist et al., 1998; 
Friedman and Halaas, 1998).Conversely, a low leptin level stimulates neuronal circuits that 
signal appetite. Thus, leptin is a homeostatic mechanism for long-term regulation of 
metabolism and body weight (Ahima et al., 1996). db/db mice harbor a point mutation in the 
gene encoding the functional isoform (LRb) of the leptin receptor. Leptin has a profound 
impact on insulin resistance and glycemic control. Evidence suggests that leptin can restore 
normal glucose levels (Pelleymounter et al., 1995) and improve insulin-sensitivity of target 
organs (Levin et al., 1996; Lin et al., 2002). In contrast, long-term hyperglycemia lowers 
leptin levels (Moriya et al., 1999). Thus leptin is a vital player for regulation of glucose 
homeostasis. There is widespread expression of LRb isoform receptors in the brain (Fei et al., 
1997; Figlewicz et al., 2003; Mercer et al., 1996). To date, the hypothalamus was considered 
as the anatomical structure required for leptin signaling in the brain. Recent evidence also 
implicates the hippocampus, cortex and amygdala with dopaminergic innervations as crucial 
for leptin mediated brain functions. There is a growing perception of involvement of leptin in 
brain disorders. Pharmacological and pathological manipulation of endogenous plasma and 
brain leptin concentration is reported in many neuropsychiatric disorders and after treatment 
with several drug classes that can affect brain functions (Asakawa et al., 2003; Baptista and 
Beaulieu, 2001; Farr et al., 2006; Lu et al., 2006). Lower brain weights, reduced cortical 
volume and decrease in total glial and neuronal protein expressions were reported in leptin-




hippocampal neuronal dendrite morphology was reported in leptin-resistant db/db mice 
(Stranahan et al., 2009). Leptin administration to leptin-deficient patients has been reported 
to increase concentration of gray matter (Matochik et al., 2005). Neurotrophic action of leptin 
was demonstrated by establishment of new neuronal circuits post-leptin treatment (Cottrell et 
al., 2010). Thus, leptin can have profound impact on the proliferation, maintenance and 
differentiation of neuronal and glial cells (Paz-Filho et al., 2008). db/db mice are resistant to 
leptin treatment because of mutation in its receptor. ob/ob mice are not refractory to leptin 
treatment and could be the important experimental tool to investigate for the possible 
involvement of leptin in diabetes related comorbid neurobehavioral complications. Leptin 
also modulates central dopaminergic neurotransmission. Overlapping leptin and DA brain 
circuitries play significant roles in type-2 diabetes as well as major neuropsychological 
disorders (Abizaid et al., 2006; Fulton et al., 2006; Gainetdinov, 2007; Moncrieff, 2009). 
Leptin receptors are colocalized with DAergic neurons in vital brain loci thereby regulating 
major DAergic pathways (Abizaid et al., 2006; Fulton et al., 2006). Reduced DA release and 
fall in TH concentration in nucleus accumbens in ob/ob mice can be rescued by leptin 
treatment (Fulton et al., 2006). Thus, leptin deficiency may contribute to some type-2 
diabetes related behavioral and neurochemical deficits.  
 
Bromocriptine 
Diminished dopaminergic tone in hypothalamic neuronal circuits was reported to induce 
insulin resistance (Luo et al., 1997; Pijl, 2003). Type-2 diabetic Zucker fa/fa rats are reported 
to have diminished D2R expression in the hypothalamus (Fetissov et al., 2002) with 




Further, D2R knockout mice experience impaired insulin response to glucose, high fasting 
glucose and glucose intolerance (Garcia-Tornadu et al., 2010a). Interestingly, activation of 
D2Rs in the ob/ob mice helped to lower diabetes-related metabolic abnormalities (Cincotta et 
al., 1997). Recently, the FDA approved D2R agonist, bromocriptine for treatment of type-2 
diabetes (de Leeuw van Weenen JE et al., 2010; Gaziano et al., 2010; Scranton and Cincotta, 
2010). Bromocriptine can normalize hyperglycemia, glucose-stimulated insulin secretion (de 
Leeuw van Weenen JE et al., 2010; Liang et al., 1998; Scislowski et al., 1999) and 
hyperleptinemia (Kok et al., 2006). It also augments the antidepressant effects of selective 
serotonin reuptake inhibitors (Renard et al., 2001). To understand role of D2Rs in type-2 
diabetes related behavioral deficits, effect of bromocriptine should be studied in db/db and 
ob/ob mice. 
 
5-HT2C receptor agonist 
Several studies also suggest involvement of serotonin (5-HT) in type-2 diabetes (Collin et al., 
2000; Trento et al., 2010). Diminished 5-HT activity is the important attribute of depression, 
psychosis and anxiety. 5-HT deficiency also contributes to impaired insulin secretion and 
glucose intolerance (Paulmann et al., 2009). While 5-HT2C receptor knockout mice 
experience insulin resistance and hyperglycemia (Xu et al., 2010), 5-HT2C receptor agonists 
improve glucose homeostasis in type-2 diabetic mice (Zhou et al., 2007). Moreover, mutation 
of the 5-HT2C receptor gene in leptin deficient ob/ob mice resulted in a synergistic worsening 
of glucose homeostasis (Wade et al., 2008). 5-HT2C receptor manipulations are also been 
considered as a novel approach in the treatment of brain disorders like schizophrenia and 




These findings indicate a close integration between 5-HT-leptin system and impaired 5-HT 
signaling may also contribute to type-2 diabetes and related neurobehavioral complications. 
Thus, restoring 5-HT neurotransmission using 5-HT2C receptor agonist such as CP 809101 




Neprilysin (NEP) is a zinc-dependent and membrane bound neutral endopeptidase. Recently, 
NEP has drawn considerable research attention because of its dual therapeutic potential in 
neurodegenerative disorders like Alzheimer’s disease (AD) (Hafez et al., 2011) and 
metabolic disorders such as diabetes (Liu et al., 2011; Zraika et al., 2007). The primary 
function of NEP is to biotransform regulatory peptides like enkephalins, endothelins and 
amyloid β (Aβ) (Johnson et al., 1999; Skidgel and Erdos, 2004). Expression of NEP was 
reported in the brain (Carter et al., 2006; Yasojima et al., 2001). Knocking out NEP gene in 
mice elevates brain Aβ levels with cognitive impairments (Iwata et al., 2001; Marr et al., 
2004; Walther et al., 2009). On the contrary, NEP over-expression and injection of NEP 
reported to decrease brain Aβ levels with improved memory functions (El-Amouri et al., 
2008; Poirier et al., 2006). Further, NEP deficiency has been shown to increase aggressive 
behavior and induce hypolocomotive behavior in mice. Thus, evaluation of role of NEP in 






10. Figures and tables 
 
Table 1. Metabolic parameters of db/db and age-matched lean control mice 
Mouse strain Lean control db/db Lean 
control 
db/db 
Age (weeks) 5 5 10 10 
Group size (n) 18-20 12-13 18-20 12-13 
Body weight (g) 19.63 ± 0.28 24.14 ± 0.6* 25.18 ± 0.56 35.97 ± 1.2* 
Blood glucose 
(mg/dL) 
145.25 ± 4.7 230.38 ± 13.25* 140.32 ± 8.81 583.20 ± 35.86* 
Plasma insulin 
(ng/ml) 
ND ND 1.27 ± 0.21 4.61 ± 1.52* 
Food intake 
(g/day/mouse) 
4.17 ± 0.13 7.43 ± 0.43* 3.85 ± 0.11 6.74 ± 0.37* 
Water intake 
(g/day/mouse) 
7.05 ± 0.13 15.66 ± 1.69* 9.76 ± 0.89 20.15 ± 2.39* 
% Fat mass 14.06 ± 1.55 42.43 ± 1.63* 17.94 ± 1.01 58.92 ± 0.75* 
% Lean mass 85.94 ± 1.55 57.57 ± 1.63* 70.43 ± 1.01 42.78 ± 1.40* 
% Body water 60.41 ± 3.94 43.84 ± 1.50* 59.62 ± 1.00 35.85 ± 1.16* 




































Fig. 1. Depression-like behavior of db/db mice. Separate groups of juvenile (5–6 weeks) and 
adult (10–11 weeks) db/db mice and their age-matched lean controls were tested for duration 
of immobility in forced swim test. Each mouse was forced to swim in water cylinder and 
scored for duration of immobility. Each bar represents means ± S.E.M. of data from 7–10 























































Fig. 2. Psychosis-like behavior of db/db mice. Different groups of juvenile (5–6 weeks) and 
adult (10–11 weeks) db/db mice and their age-matched lean controls were tested for PPI 
behavior. Each mouse was subjected to 5 types of trials and each trial was presented 10 times 
as pulse alone (85 dB or 100 dB white noise), pre-pulse alone (70 dB) and pre-pulse + pulse 
(70 dB + 85 dB or 70 dB + 100 dB) in randomized fashion (total trials: 5 × 10 = 50) with 
background noise (60 dB) in startle chambers and their startle responses to these stimuli (in 
Newtons; Max[N]) were recorded using pressure-sensitive plates. Each bar represents means 


















































































Fig. 3. Anxiolytic behavior of db/db mice showing a) Percent time spent in open arms b) 
Percent open arms entries and c) Open arms distance traveled (inches) on elevated plus maze. 
Different groups of juvenile (5–6 weeks) and adult (10–11 weeks) db/db mice and their age-
matched lean littermates were subjected to 5 min elevated plus maze test. Each bar represents 







































































Fig. 4. Hypo-locomotive and thigmotaxis behavior of db/db mice in open field test showing a) 
Basic movements b) Fine movements and c) Percent time spent in periphery. Different groups 
of juvenile (5–6 weeks) and adult (10–11 weeks) db/db mice and their age-matched lean 
controls were subjected to 10 min open field test. Each bar represents means ± S.E.M. of data 





































































Fig. 5. Working memory test in db/db mice. Different groups of juvenile (5–6 weeks) and 
adult (10–11 weeks) db/db mice and their age-matched lean controls were subjected to 8 min 
Y-maze test and scored for a) total arm entries, b) alternations and c) percent Y-maze scores. 
Each bar represents means ± S.E.M. of data from 7–10 mice per group. *p < 0.05 vs. age-























































































































Fig. 6. Dopamine (DA) concentrations in distinct brain regions of db/db mice. Frontal cortex, 
67mygdale, hippocampus, hypothalamus and brainstem of 11-12 week old db/db mice and 
age-matched lean controls were evaluated for DA concentrations by reverse-phase HPLC. 
Each bar represents means ± S.E.M. of data from 7-10 mice per group. *p < 0.05 vs. age-

























































































































Fig. 7. Homovanillic acid (HVA) concentrations in distinct brain regions of db/db mice. 
Frontal cortex, amygdala, hippocampus, hypothalamus and brainstem of 11-12 week old 
db/db mice and age-matched lean controls were evaluated for HVA concentrations by reverse-
phase HPLC. Each bar represents means ± S.E.M. of data from 7-10 mice per group. *p < 







































































































































Fig. 8. Dihydroxyphenylacetic acid (DOPAC) concentrations in distinct brain regions of 
db/db mice. Frontal cortex, amygdala, hippocampus, hypothalamus and brainstem of 11-12 
week old db/db mice and age-matched lean controls were evaluated for DOPAC 
concentrations by reverse-phase HPLC. Each bar represents means ± S.E.M. of data from 7-
10 mice per group. *p < 0.05 vs. age-matched lean control mice; non-parametric unpaired t-




































































Fig. 9. HVA/DA ratios in distinct brain regions of db/db mice. Frontal cortex, amygdala, 
hippocampus, hypothalamus and brainstem of 11-12 week old db/db mice and age-matched 
lean controls were evaluated for DA and HVA concentrations. HVA/DA ratios were 
calculated as an index of DA usage. Each bar represents means ± S.E.M. of data from 7-10 
mice per group. *p < 0.05 vs. age-matched lean control mice; non-parametric unpaired t-test 













































































 Fig. 10. DOPAC/DA ratios in distinct brain regions of db/db mice. Frontal cortex, amygdala, 
hippocampus, hypothalamus and brainstem of 11-12 week old db/db mice and age-matched 
lean controls were evaluated for DA and DOPAC concentrations. DOAPC/DA ratios were 
calculated as an index of DA usage. Each bar represents means ± S.E.M. of data from 7-10 
mice per group. *p < 0.05 vs. age-matched lean control mice; non-parametric unpaired t-test 





















































































































Fig. 11. Norepinephrine (NE) concentrations in distinct brain regions of db/db mice. Frontal 
cortex, amygdala, hippocampus, hypothalamus and brainstem of 11-12 week old db/db mice 
and age-matched lean controls were evaluated for NE concentrations by reverse-phase HPLC. 
Each bar represents means ± S.E.M. of data from 7-10 mice per group. *p < 0.05 vs. age-



























































































































Fig. 12. 5-Hydroxytryptamine (5-HT) concentrations in distinct brain regions of db/db mice. 
Frontal cortex, amygdala, hippocampus, hypothalamus and brainstem of 11-12 week old 
db/db mice and age-matched lean controls were evaluated for 5-HT concentrations by reverse-
phase HPLC. Each bar represents means ± S.E.M. of data from 7-10 mice per group. *p < 




































Fig. 13. Effect of rosiglitazone on blood glucose levels in lean control and db/db mice. 5-6 
week old db/db mice and their age-matched lean controls were fed with either standard chow 
or rosiglitazone-mixed chow (71 mg/kg chow, 20 mg/kg/day p.o.) (n = 5-8) for 5 weeks and 
weekly monitored for blood glucose concentration. Each bar represents means ± S.E.M. of 












































































Fig. 14 Rosiglitazone treatment improved glucose utilization by db/db mice. Separate groups of 
db/db mice and their age-matched lean controls were administered either standard chow or 
rosiglitazone-mixed chow (71 mg/kg chow, 20 mg/kg/day p.o.) (n = 5-8) for 5 weeks. Mice 
were fasted overnight. Blood glucose concentrations were measured at 0, 15, 30, 45, 60, 90 and 
120 minute post-glucose (1.5 gm/kg, i.p.) injection from the blood samples taken from cut made 
on tip of mouse tail. Area under the curve (AUC) was calculated to study treatment effect on 
mouse’s glucose tolerability. Each bar represents means ± S.E.M. of data from 5-13 mice per 







Fig. 15. Rosiglitazone reversed depression-like behavior of db/db mice. 5-6 week old db/db 
mice and their age-matched lean controls were fed with standard chow or rosiglitazone-mixed 
chow (71 mg/kg chow, 20 mg/kg/day p.o.) (n = 5-8) for 5 weeks. 10-11 week old mice were 
tested for duration of immobility in the forced swim test. Each mouse was forced to swim in 
water cylinder and scored for duration of immobility. Each bar represents means ± S.E.M. of 
data from 5-8 mice per group. *p < 0.05 vs. age-matched lean control mice; #p < 0.05 vs. age-























































Fig. 16. Rosiglitazone treatment does not reverse hypolocomotive behavior of db/db mice. 5-6 
week old db/db mice and their age-matched lean controls were fed with standard chow or 
Rosiglitazone-mixed chow (71 mg/kg chow, 20 mg/kg/day p.o.) (n = 5-8) for 5 weeks. 10-11 
week old mice were scored for A) Basic movements and B) Fine movements in open field 
test. Individual mice were subjected to 10 minute open field test. Each bar represents means ± 


























































Fig. 17. Rosiglitazone treatment does not reverse psychosis-like behavior of db/db mice. 5-6 
week old db/db mice and their age-matched lean controls were fed with standard chow or 
Rosiglitazone-mixed chow (71 mg/kg chow, 20 mg/kg/day p.o.) for 5 weeks. 10-11 week old 
mice were tested for PPI behavior. Each mouse was subjected to 5 types of trials and each 
trial was presented 10 times as pulse alone (85 dB or 100 dB white noise), pre-pulse alone (70 
dB) and pre-pulse + pulse (70 dB + 85 dB or 70 dB + 100 dB) in randomized fashion (total 
trials: 5 x 10 = 50) in startle chambers and their startle responses to these stimuli (in Newtons; 
Max[N]) were recorded using pressure-sensitive plates. Each bar represents means ± S.E.M. 




























Fig. 18. Rosiglitazone does not alter db/db mouse behavior in the fear potentiated startle test. 
5-6 week old db/db mice and their age-matched lean controls were fed with standard chow or 
Rosiglitazone-mixed chow (71 mg/kg chow, 20 mg/kg/day p.o.) (n = 5-8) for 5 weeks. 10-11 
week old mice were tested for FPS behavior. During pre-test and post-test each mouse was 
subjected to 2 different trials (i) startle stimulus (85 dB white noise startle stimulus) and (ii) 
startle stimulus with tone (70dB, 30 s., 12 kHz pure tone plus 85 dB white noise) with an 
inter-trial interval of 1 min. Each trial was repeated 8 times and presented in randomized 
fashion (total = 16 trials). The % FPS responses for were calculated. The 2-day training phase  
preceded to post-test was consisted of 20 trials/day [70dB, 30 s., 12 kHz (conditioned 
stimulus, CS) tone] overlapping and terminating with a 500 ms 0.4 mA shock (unconditioned 
























































































































Fig. 19. Effect of rosiglitazone treatment on DA concentrations in distinct brain regions of 
db/db mice. Frontal cortex, amygdala, hippocampus, hypothalamus and brainstem of 11-12 
week old db/db mice and age-matched lean controls were evaluated for DA concentrations by 
reverse-phase HPLC. Each bar represents means ± S.E.M. of data from 7-10 mice per group. 























































































































Fig. 20. Effect of rosiglitazone treatment on HVA concentrations in distinct brain regions of 
db/db mice. Frontal cortex, amygdala, hippocampus, hypothalamus and brainstem of 11-12 week 
old db/db mice and age-matched lean controls were evaluated for HVA concentrations by 
reverse-phase HPLC. Each bar represents means ± S.E.M. of data from 7-10 mice per group. *p 











































































































































Fig. 21. Effect of rosiglitazone treatment on DOPAC concentrations in distinct brain regions of 
db/db mice. Frontal cortex, amygdala, hippocampus, hypothalamus and brainstem of 11-12 week 
old db/db mice and age-matched lean controls were evaluated for DOPAC concentrations by 
reverse-phase HPLC. Each bar represents means ± S.E.M. of data from 7-10 mice per group. *p 





































































Fig. 22. Effect of rosiglitazone treatment on HVA/DA ratios in distinct brain regions of db/db 
mice. Frontal cortex, amygdala, hippocampus, hypothalamus and brainstem of 11-12 week old 
db/db mice and age-matched lean controls were evaluated for DA and HVA concentrations. 
HVA/DA ratios were calculated as an index of DA usage. Each bar represents means ± S.E.M. of 
data from 7-10 mice per group. *p < 0.05 vs. age-matched lean control mice; #p < 0.05 vs. age-
















































































Fig. 23. Effect of rosiglitazone treatment on DOPAC/DA ratios in distinct brain regions of db/db 
mice. Frontal cortex, amygdala, hippocampus, hypothalamus and brainstem of 11-12 week old 
db/db mice and age-matched lean controls were evaluated for DA and DOPAC concentrations. 
DOPAC/DA ratios were calculated as an index of DA usage. Each bar represents means ± 
S.E.M. of data from 7-10 mice per group. *p < 0.05 vs. age-matched lean control mice; #p < 0.05 






Fig. 24. Effect of rosiglitazone treatment on tyrosine hydroxylase (TH) expression in the frontal 
cortex of db/db mice. Unpaired t-test showed that there was no significant change in the TH 
expression in the db/db mice compared to age-matched lean control (p > 0.05). Each bar 
represents means ± S.E.M. of data from n = 3 sample wells per group. *p < 0.05 vs. age-matched 







Fig. 25. Effect of rosiglitazone treatment on tyrosine hydroxylase (TH) expression in the 
amygdala of db/db mice. Unpaired t-test showed that there was no significant change in the TH 
expression in the db/db mice compared to age-matched lean control (p > 0.05). Each bar 
represents means ± S.E.M. of data from n = 3 sample wells per group. *p < 0.05 vs. age-matched 







Fig. 26. Effect of rosiglitazone treatment on tyrosine hydroxylase (TH) expression in the 
hypothalamus of db/db mice. Unpaired t-test showed that there was no significant change in the 
TH expression in the db/db mice compared to age-matched lean control (p > 0.05). Each bar 
represents means ± S.E.M. of data from n = 3 sample wells per group. *p < 0.05 vs. age-matched 







Fig. 27. Effect of rosiglitazone treatment on adrenal catecholamines levels of db/db mice. 1-way 
ANOVA showed that there was significant increase in the adrenal NE, E and DA levels in the 
db/db mice compared to age-matched lean control (p < 0.05). Each bar represents means ± 
S.E.M. of data from n = 6-7 mice per group. 5-week rosiglitazone treatment helped to bring such 





Table 2. Summary of type-2 diabetes related changes in DA metabolism and biosynthesis pattern 
in selective brain regions of db/db mice compared to age-matched lean controls.   
Brain region DA HVA DOPAC HVA/DA DOPAC/DA TH/-actin 
Frontal cortex No change Increased Increased Increased Increased No change 
 
 
Inference: Changes in DA metabolism in the frontal cortex of db/db mice may be related to 
increased enzymatic activity of DA metabolizing enzymes and/or altered neuronal 
firing. 
 
Brain region DA HVA DOPAC HVA/DA DOPAC/DA TH/-actin 
Amygdala Increased Increased Increased Decreased Decreased No change 
 
Inference: Changes in DA metabolism in the  amygdala of db/db mice may be related to 
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